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Introduction: Type 2 diabetes mellitus (T2DM) is by far the most prevalent form of 
diabetes manifesting with insulin resistance (IR), abnormal pancreatic β-cell function 
and hyperglycaemia. Evidence from epidemiological and observational studies have 
shown that vitamin D deficiency is associated with increased risk for T2DM although 
the findings are inconsistent and inconclusive. In the circulation vitamin D is 
transported bound to vitamin D binding protein (VDBP), evidence showed that vitamin 
D levels are positively associated with VDBP levels. Several genes such as vitamin D 
receptor gene (VDR), involved in the metabolic pathway of T2DM have been 
considered good candidate for susceptibility to T2DM. The present study aimed to 
investigate the association between vitamin D, vitamin D binding proteins (VDBP) and 
vitamin D receptor (VDR) polymorphisms in T2DM and non-diabetic patients in the 
mixed ancestry population.  
Materials and methods: The current study comprised of 1603 participants (387 
males and 1216 females). Vitamin D levels were measured using the paramagnetic 
particle chemiluminescence test on a Beckman DXI. Vitamin D binding protein (VDBP) 
in serum samples was measured using the Human Vitamin D BP Quantikine ELISA 
kit. Fok1 (rs2228570), Apa1 (rs7975232) and Taq1 (rs731236) single nucleotide 
polymorphisms (SNPs) of the VDR gene were genotyped from a genomic DNA using 
the TaqMan SNP Genotyping Assays and were confirmed by direct sequencing.  
Results: Vitamin D deficiency (44%) and insufficiency (42.6%) were highly prevalent 
and optimal 25(OH)D levels were very low with only 13% having optimal levels. The 
overall vitamin D status of the whole population group was insufficient (22.0±7.6 
ng/mL). 25(OH)D levels and serum VDBP varied according to gender with males 
having higher 25(OH)D levels (23.6±7 vs 21.5±7.5ng/mL, P=0.0006) and females with 
significantly higher serum VDBP levels (299.1±71.2 vs 315.9±76.1 µg/mL, P<0.0001). 
25(OH)D levels were generally significantly decreased in the hyper-glycemic 
subgroups.  Screen-detected DM males had low 25(OH)D levels compared to normo-
glycaemic group (17.0±6.1vs 24.2±8.2, P=0.0214). A similar trend was observed in 
the female groups (21.1±6.0 vs 22.4±7.9, P=0007). Anthropometric measurements 
including the BMI (kg/m2), Waist C (cm) and Hip C (cm) were significantly higher in 
hyper-glycaemic group than in normo-glycaemic males and females (All, P<0.0001). 





In contrast, there were no significant differences in serum VDBP (µg/mL) between the 
glycaemic sub-groups in either male (P=0.5614) or females (P= 0.4813). The 
glycaemic parameters, as expected, were significantly increased in the hyper-
glycaemic sub-groups in both genders, including FBG (mmol/L), 2 hr BG (mmol/L), 
HbA1c (%), FBI (mIU/L), 2 hr BI (mIU/L) and HOMA-IR (All, both males and females 
P<0.0001). In general, the lipids, including the triglycerides (mmol/L), LDL-C (mmol/L) 
and Cholesterol (mmol/L) were also significantly increased in both genders in the 
hyper-glycaemic sub-groups (All, males P≤0.0300, females P<0.0001), while HDL-C 
(mmol/L) was significantly decreased in both males and females in the hyper-
glycaemic sub-groups (All, P≤0.0308). 
The variant genotype GG of the Fok1, AA of Apa1 and GG of the Taq1 SNPs were 
not significantly different in hyper-glycaemic patients compared to normo-glycaemic 
group (58.5% vs 55.1%, P-value, 40.1% vs 38.0%, P-value and 6.9% vs 8.5%, P-
value,) respectively. Similarly, there was no significant difference in the alleles 
frequency distribution of these SNPs between the groups. Results also demonstrated 
no significance difference in the genotype or allele frequency distribution of Fok1 
(rs2228570), Apa1 (rs7975232) and Taq1 (rs731236) SNPs between subjects with 
optimal Vitamin D (25(OH)D ng/mL) levels and those with insufficient/deficient levels 
(P≥0.2036 and P≥0.6347 respectively). These trends were also observed when serum 
VDBP levels were evaluated against Fok1, Apa1 and Taq1 genotypes. 
Multiple linear regression showed that low 25(OH)D was associated with increased 
LDL-C and PTH in both male and females irrespective of T2DM, but serum VDBP was 
associated with low 25(OH)D in hyper-glycaemic females only. In normo-glycaemic 
males 19.5% of the variation in 25(OH)D was attributed to increased LDL-C and in the 
hyper-glycaemic group 15.5% it was attributed to PTH and CRP. In normo-glycaemic 
females 12.8% variation in 25(OH)D was attributed to LDL-C, serum creatinine and 
PTH, whereas in hyper-glycaemic group 16.1% was attributed to increased age, 
serum VDBP, triglycerides, LDL-C, creatinine and PTH. 
Conclusion:  This study showed prevalence of vitamin D deficiency/insufficiency in 
the mixed ancestry population group. There was no association between vitamin D 
(25(OH)D), vitamin D binding proteins (serum VDBP) and VDR polymorphisms in 
T2DM patients. Serum VDBP levels were associated with low vitamin D levels in 





hyper-glycaemic females only. Increased LDL-C, PTH and CRP were predictors of low 
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Definition of concepts 
Diabetes mellitus                 : Is a group of metabolic disorders characterized by 
raised glucose levels in the blood resulting from defects 
in insulin secretion, insulin resistance or both 
Metabolic syndrome            : Is a cluster of metabolic disorders occurring at ones 
thus increasing risk for Type 2 diabetes mellitus and 
cardiovascular diseases. 
Insulin resistance                : Is a pathological condition in which the body cells do not 
respond to the effects of hormone insulin                
Vitamin D deficiency            : Is defined as vitamin D levels below 20ng/ml in the   
                                               blood circulation. 
Vitamin D insufficiency        : Is defined as vitamin D levels below above 20ng/ml but 
below 30ng/ml in the blood circulation 
Vitamin D                             : Is a lipid soluble vitamin responsible for maintenance of 
body mineral homeostasis and bone health  
Vitamin D Binding Protein   : Is a glycoprotein responsible for transporting vitamin D 
in the circulation to vitamin D requiring cells. 
Vitamin D receptor               : Is a steroid/thyroid hormone receptor superfamily that 














Chapter 1 Introduction 
The frequency of diabetes mellitus is rapidly increasing globally. More recently, the 
International Diabetes Federation (IDF) estimates shows that 415 million (uncertainty: 
340-536 million) people aged 20-79 years had diabetes in the year 2015 (Ogurtsova 
et al., 2017). Diabetes was accountable for about 5.0 million deaths. About a quarter 
(75%) of these diabetic cases resides in the low-and middle-income countries (LMICs). 
This number of type 2 diabetes cases is projected to rise to 642 million (uncertainty: 
interval of 521-829 million) in 2040. Type 2 diabetes mellitus (T2DM) is the most 
prevalent form of diabetes manifesting with insulin resistance, abnormal pancreatic β-
cell function and hyperglycaemia (Takiishi  et al., 2010). T2DM is a major cause of 
morbidity and mortality accounting for over 90% diabetes cases globally. Several 
genetic and environmental factors have been implicated in its onset and progression. 
It is known that pathophysiology of T2DM involves impaired insulin secretion with a 
coexisting insulin resistance (Pittas et al., 2010). Studies have shown that high vitamin 
D levels can enhance pancreatic β-cell function and improve insulin resistance (Pittas 
et al., 2010); (Ozfirat et al., 2010). Vitamin D exerts its cellular functions through 
binding Vitamin D receptor (VDR) (Al-Daghri et al., 2012), an intracellular hormone 
receptor which belongs to steroid hormone receptor superfamily (Wang et al., 2012). 
Thus, VDR gene is considered an important candidate gene for susceptibility to type 
2 diabetes mellitus (T2DM) (Abdeltif et al., 2014). Furthermore, genetic alterations in 
the VDR gene may lead to defects in gene activation or alter protein function/structure 
of which could affect both the binding and affinity of vitamin D and its functions. 
Currently, Fok1, Bsm1, Apa1 and Taq1 single nucleotide polymorphisms (SNPs) of 
the VDR gene are the commonly  studied VDR polymorphisms in relation to T2DM 
susceptibility, cancers, autoimmune and infectious diseases (Uitterlinden et al., 2004).  
Correlations between VDR polymorphisms and parameters associated with T2DM 
such as glucose intolerance, insulin insensitivity, altered insulin secretion and vitamin 
D deficiency have been reported (Valdivielso et al., 2006). Numerous studies have 
examined the association between these four polymorphisms and T2DM risk. 
However, their results were inconsistent and inconclusive across various ethnic 
populations.  
 





There is no available data on the association of vitamin D, vitamin D binding proteins 
and VDR polymorphisms in the mixed ancestry population of Bellville South, Cape 
Town, South Africa despite a high prevalence (28%) of T2DM being reported in this 
population group (Erasmus et al., 2012).Therefore, the current study aims to examine 
the association between vitamin D levels, vitamin D binding proteins and VDR 
polymorphisms in diabetic and non-diabetic patients within the mixed ancestry 
population-group.





Chapter 2 Literature review. 
2.1 Definition of diabetes. 
Diabetes mellitus (DM) is defined as a group of metabolic diseases characterized by 
hyperglycaemia resulting from defects in insulin secretion and insulin action or both 
(American Diabetes Association, 2014). The chronic hyperglycaemia of diabetes is 
associated with long-term damage, dysfunction and failure of various organs mainly 
the eyes, kidneys, nerves, heart and blood vessels (American Diabetes Association, 
2014). Several pathogenic processes are implicated in the onset and progression of 
diabetes. These include autoimmune destruction of the pancreatic β-cells resulting in 
insulin deficiency or inadequate insulin action to target cells or tissues (American 
Diabetes Association, 2014).  
2.2 Classification of diabetes mellitus. 
Diabetes mellitus is classified into two major types: type 1 diabetes mellitus (T1DM) 
and type 2 diabetes mellitus(T2DM). Other less common types include gestational 
diabetes mellitus (GDM) and maturity-onset of the young (MODY) and latent diabetes 
in adults (LADA). 
2.2.1 Type 1 diabetes mellitus (T1DM). 
The pathophysiology of T1DM involves autoimmune destruction of  pancreatic β-cells 
thus resulting in absolute insulin deficiency and hyperglycaemia (Mohammadnejad et 
al., 2012);(Gregory et al., 2013). T1DM is formerly known as insulin dependent 
diabetes mellitus (IDDM) or juvenile onset diabetes mellitus. Immune destruction of 
the pancreatic β-cells is marked by presence of the autoantibodies of islet cells, insulin 
autoantibodies and autoantibodies to the glutamic acid decarboxylase 65 (GAD65). 
These abovementioned autoantibodies are present after the initial detection of 
hyperglycaemia. (Amercan Diabetes Association, 2010). 
This disease predominantly affects children, adolescents and adults aged below 30 
years old (Mohammadnejad et al., 2012).  It accounts for about 5-10% of cases with 
diabetes mellitus and majority of diagnosed cases are children. Lack of insulin lead to 
dysregulation of glucose levels in the body, thus limiting glucose transport to the target 
cells. Hence, that leads to increased gluconeogenesis and lipolysis, which in turn 
results with the formation of ketone bodies (acetoacetic acid and β-hydroxybutyric acid 





and acetone) from lipolysis (Gregory et al., 2013). Accumulation of these metabolites 
in blood circulation lead to development of diabetic ketoacidosis (DKA). DKA is the 
major cause of death in children suffering from T1DM (Cooke et al., 2008). 
2.2.2 Type 2 diabetes mellitus (T2DM). 
T2DM Formerly known as non-insulin dependent diabetes mellitus (NIDDM) or adult 
onset diabetes mellitus is characterized by raised blood sugar levels or 
hyperglycaemia arising from two pathological conditions, namely: insulin resistance 
and β- cell dysfunction (Holt et al., 2004); (Cerf et al., 2013) . Studies have reported 
that obesity has led to a dramatic increase in the incidence of T2DM more especially 
among children and adolescents (Haemer et al., 2014). In addition, obesity is strongly 
associated with insulin resistance of which when coupled with insulin deficiency it 
leads to an overt T2DM (Haemer et al., 2014). Insulin resistance refers to a condition 
characterized by impaired ability of the insulin to transport glucose to the target cells, 
whilst β- cell dysfunction refers to suboptimal or insufficient secretion of insulin from 
the β-cells (Holt et al., 2004). The above-mentioned disorders disturb the maintenance 
of glucose homeostasis. Accumulating evidence showed that insulin resistance and β-
cell dysfunction predicted the development of T2DM independently of known and 
unknown risk factors.   
2.2.3 Gestational diabetes mellitus (GDM).   
Gestational diabetes mellitus is an overt diabetes that occurs in up to 2-5% of pregnant 
women during pregnancy. It can thus lead to serious complications for the mother and 
child and they are both at high risk for developing T2DM at later life (Ben-Haroush et 
al., 2004); (Chu et al., 2007). Complications include preeclampsia or hypertension 
during pregnancy, premature birth and respiratory distress syndrome and still birth or 
dead foetus (Bodnar et al., 2010). Risk factors for GDM include obesity, previous 
history of GDM, advanced age≥ 25 years old and family history of diabetes (Zhang et 
al., 2011). 
In addition, a meta-analysis found that high maternal weight (overweight and obesity) 
is associated with substantially increased risk for GDM as compared to lean women 
(Chu et al., 2007). Also increased insulin resistance and lack of physical activity 
contributes to increased risk for GDM. GDM is caused by failure of the insulin action 
to regulate glucose levels during pregnancy thus resulting in hyperglycaemia in the 





circulation and insulin resistance (Barbour et al., 2007). Insulin resistance during 
pregnancy is also caused by the effect of substances released by placenta which 
tempers with the normal function of insulin (Barbour et al., 2007). 
2.2.4 Maturity-onset diabetes of the young (MODY). 
Maturity-onset diabetes of the young is a very rare form of T2DM, characterized by 
hyperglycaemia, impaired insulin secretion with minimal or no defects in insulin action 
due to mutations in insulin genes (American Diabetes Association, 2014). This disease 
is inherited in an autosomal dominant pattern, thus it accounts for 1-2% of all diabetic 
cases (Shields et al., 2010). MODY patients are often misdiagnosed as T1DM/T2DM. 
This disease is also characterized by its early onset at early childhood, adolescent or 
age below 25 years. 
2.2.5 Latent Autoimmune Diabetes in Adults (LADA). 
Latent autoimmune diabetes of the adults (LADA) is an autoimmune diabetes defined 
by adult-onset ≥ 35 years, presence of diabetes associated autoantibodies (DAA), and 
no insulin treatment requirement for a period after diagnosis (Laugesen et al., 2015). 
LADA accounts for about 12% of all diabetic cases in adult populations (Naik et al., 
2009). Common DAA includes glutamic acid decarboxylase 65 (GAD65), insulinoma 
antigens IA-2 (IA-I2), islet cells and zinc transporter 8 (Lampasona et al., 2010). 
Immunologically GAD65 is the most prevalent form of autoantibody presence in adult 
onset diabetes. This disease shares genetic features with both T1DM and T2DM. 
LADA patients are often misdiagnosed as T2DM, due to similar phenotypic 
appearance and disease age-onset (Appel et al., 2009). Moreover, LADA patients 
have worse HbA1c levels as compared to T2DM. accumulating evidence have shown 
LADA tend to have lower mean age at onset, lower BMI and more frequent need for 
insulin treatment than T2DM patients (Laugesen et al., 2015). Patients with LADA 
have slow β- cell destruction thus insulin treatment is not required at the time of 
diagnosis (Appel et al., 2009). 
2.3 Risk factors for type 2 diabetes mellitus (T2DM). 
Type 2 diabetes (T2DM) is a multifactorial disease which arises from the complex 
interaction of both modifiable and non-modifiable risk factors. These risk factors may 
range from genetic level to environmental. 





2.3.1 Modifiable risk factors. 
2.3.1.1 Obesity and body fat distribution 
Obesity is one of the modifiable risk factors for T2DM, it has been extensively studied. 
It is defined as body mass index (BMI) ≥ 30 kg/m2, this unit of measure has been 
traditionally used to determine prevalence of obesity in national population based 
studies (Nguyen et al., 2010). It has been reported that the increase in obesity has 
been accompanied by an increasing prevalence of T2DM. Since obesity is such a 
strong predictor of T2DM incidence, then the higher prevalence of T2DM reported 
among different populations previously is almost certainly attributed to an increase in 
obesity rates. A meta-analysis has shown a strong association between  measures 
reflecting abdominal obesity such as waist circumference (WC) and the development 
of Type 2 diabetes (Freemantle et al., 2008). It is therefore assumed that reducing WC 
may reduce the development of T2DM. 
Abdominal obesity is known as the combination of subcutaneous and visceral fat and 
has been widely reported as risk factors for T2DM and is also associated with a poor 
metabolic profile (Freemantle et al., 2008). The association between increased 
abdominal obesity and T2DM can be partly attributed to the increased release of non-
esterified fatty acids (NEFA) and production of pro-inflammatory cytokines from the 
abdominal fat depot (Karpe et al., 2011). Higher NEFA and production of pro-
inflammatory cytokines are believed to alter insulin signalling thus resulting in insulin 
resistance (Kahn et al., 2006); (Karpe et al., 2011). Furthermore, production of these 
metabolites increases with the degree of obesity. 
2.3.1.2 Physical Activity (PSA) 
Engagement in physical activity is the most recommended key factor for the prevention 
and management of T2DM, Hence both obesity and increased sedentary lifestyle are 
considered as risk factors for the development of T2DM (Gajardo et al., 2017) with the 
former being a higher contributor to T2DM risk compared to physical inactivity (Rana 
et al., 2007)   
According to WHO, insufficient PSA is defined as less 150 minutes of moderate 
physical activity per week or equivalent. In Africa about a quarter of men and women 
presented with insufficient PSA. A study from Iran reported that moderate physical 
activity ≥150 min/week was associated with reduced risk for T2DM in all non-obese 





people, however in obese such an effect was not observed (Ghaderpanahi et al., 
2011). In a multi-ethnic study of atherosclerosis (MESA), the incidence type 2 diabetes 
was significantly and inversely associated with exercise and vigorous physical activity, 
typical walking pace, and conversely associated with sedentary lifestyle (Joseph et al., 
2016).  This indicates that moderate to vigorous intensity physical activity may reduce 
the risk for development of T2DM and in obese individuals moderate physical activity 
should be increased.   
2.3.1.3 Poor diet. 
Diet is considered as a modifiable risk factor for T2DM. Accumulating evidence have 
shown that high consumption of refined carbohydrates, saturated and trans fats is 
associated with an increased risk for T2DM by adversely affecting glucose metabolism 
and insulin resistance (Hu et al., 2001).Furthermore, evidence also suggests that 
consumption of different micronutrients could contribute to increased risk for 
development of T2DM.  Studies have shown that a high intake of food rich in fibre such 
as whole grain-cereals contributes to reduction in HOMA-IR and lower prevalence of 
metabolic syndrome (McKeown et al., 2004). Moreover, a multi-ethnic cohort study 
reported that food high in meat and fat confers higher diabetes risk in all ethnic groups, 
although the effects of other dietary patterns substantially differ by sex and 
race/ethnicity (Erber et al., 2009).In addition, evidence demonstrates that beneficial 
effect of the micronutrient such as vitamin D is not limited to bone health but also to 
non-skeletal diseases including cancer, autoimmune disorders, cardiovascular 
disease and T2DM (Engelman et al., 2010).  The protective role of vitamin D against 
the development of T2DM will be discussed in detail later.  
2.3.1.4 Hypertension. 
In the literature there is considerable evidence for an increased prevalence of 
hypertension in diabetic patients from other populations  have shown a sharp increase 
in the prevalence of hypertension in diabetic patients (Berraho al., 2012). According 
to ADA guidelines (2018), hypertension is defined as a sustained systolic blood 
pressure of (≥140 mmHg) over diastolic blood pressure of (≥90 mmHg).  Both diabetes 
and hypertension predispose patients to the development of CVDs and renal diseases. 
For example, prospective cohort study comprised of 12550 adults have shown that the 
development of T2DM was almost 2.5 times as likely in persons with hypertension 
than in their normotensive counterparts (Berraho al., 2012);(Sowers et al., 1995). 





Furthermore, the age adjusted relative risk of death consequent to cardiovascular 
events in T2DM patients is 3-fold higher than in the general population (El-Atat et al., 
2004). Additionally, the presence of hypertension in T2DM patients substantially 
increases the risk of coronary heart diseases, stroke, neuropathy and retinopathy. 
Therefore, blood pressure control is vital and necessary for prevention of the 
development of T2DM and CVDs in the general population. In patients with diabetes, 
the Joint National Committee on the Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) recommends a target BP of <130/80mmHg in order to prevent 
death and disability associated with high BP. 
2.3.1.5 Lipids abnormalities. 
Abnormal plasma lipids, characterized by elevated triglycerides and reduced HDL-C, 
often by elevated apolipoprotein B and non-HDL-C particles are common in patients 
with established CVDs, T2DM and obesity or metabolic syndrome (Fruchart et al., 
2008). In patients with diabetes this pattern of lipids is termed diabetic dyslipidaemia 
which is one of the modifiable risk factors for T2DM. HDL-C is required for clearance 
of excess cholesterol from peripheral tissues. However, when HDL-C is reduced, then 
triglycerides, very low-density lipoprotein (VLDL-C) and LDL-C are all elevated (Daniel 
et al., 2011). The particle size of LDL-C in patients with diabetes is so small and  
denser because of elevated triglycerides (Feldman et al., 2018). Elevated triglycerides 
result from either abnormal overproduction of VLDL-C or impaired lipolysis of 
triglycerides. Evidence state that patients with T2DM have overproduction of VLDL-C 
level, which is consequent to elevated free fatty acids, hyperglycaemia, obesity and 
insulin resistance (Mooradian et al., 2009). several studies confirmed that lowering 
LDL-C benefits equally both patients with diabetes and without diabetes (Fruchart et 
al., 2008). 
2.3.2 Non-modifiable risk factors. 
2.3.2.1 Advanced Age. 
Older age is a well-known risk factor for T2DM. Evidence have shown that increased 
prevalence of T2DM and impaired glucose tolerance increases with aging (Chang et 
al., 2003). In addition, the prevalence of diabetes is more than two times higher among 
elderly adults as compared to middle age or young adults and there is high number of 
incidence diabetic cases (Cowie et al., 2009). Data from the National Health Survey 





have shown rapid rise in the incidence of T2DM among elderly population group. The, 
incidence of diabetes observed in adults aged 65-79 years per 1000 population was 
6.0% in 1990, 11.6% in 2000 and 12.4% in 2010 (Corriere et al., 2013). Consequent 
to high incidence of diabetes in  aging populations, it is then projected that number of  
diabetic cases aged ≥65 years will grow more than 4-fold between 2005 and  2050 
(Narayan et al., 2006). There is also evidence which indicates that older individuals 
develop insulin resistance due to reduced physical activity, obesity and loss of lean 
body mass, particularly those with a disproportional loss of skeletal muscles (Lee et 
al., 2017). 
2.3.2.2 Ethnicity. 
Ethnicity is considered as a non-modifiable risk factor for diabetes with certain ethnic 
groups being at an increased risk for developing T2DM. An epidemiological study from 
the U.S. found different prevalence rate of diagnosed diabetes mellitus among adults 
aged ≥ 20 years old (Spanakis et al., 2013). An increased burden of diabetes was 
observed in Native Americans (33%) compared to Alaska Natives (5.5%). In addition, 
similar prevalence rates were observed between the Non-Hispanic whites (7.1%) and 
Asian Americans (8.4%), whereas Non-Hispanic Blacks and Hispanics Americans had 
higher prevalence rates of 11.8% and 12.6% respectively (Spanakis et al., 2013). 
Another study showed that prevalence of type 2 diabetes ranges from 2% in China to 
50% in Pima Indians (Singh et al., 2004). Immigrants in Sweden from the Middle East 
have 2-3-fold increased risk of T2DM compared to native Swedes. Moreover, these 
immigrants seem to have a slightly different form of diabetes with early onset and lower 
C-peptide as compared to Swedish patients. This form of diabetes is also common in 
patients from Middle East (Glans et al., 2008). 
In South Africa Indians have the highest prevalence of diabetes, followed by 8-10% in 
the Mixed ancestry community (8-10%), 5-8% among blacks and 4% among whites. 
The large difference in the prevalence of diabetes among ethnic groups exists also 
due to the influence of genetics and environmental factors. Hence, Indians in South 
Africa seem to have high genetic predisposition for diabetes susceptibility compared 
to other ethnic groups. In addition, increased obesity is another factor that contributes 
to dramatic increase in the T2DM prevalence among ethnic groups.  






An ample body of evidence suggests that there is a genetic component to T2DM risk. 
The heritability of this disease ranges from 20-80% and evidence is observed from 
family population and twin-based studies (Meigs et al., 2000);(Poulsen et al., 1999). 
Several family studies have observed increased risk for T2DM when one or both 
parents are diagnosed of the disease. For example, study showed that among black 
South African patients with positive history of diabetes about 82.7% of them had first 
degree relative with diabetes (Erasmus et al., 2001). In addition, there was a significant 
maternal aggregation with 64.7% having diabetic mother compared with 27% of those 
who had diabetic father. This data was corroborated by observed high prevalence of 
T2DM in patients with diabetic mother (25.4% vs 22.1) and maternal uncles/aunts 
(31.2% vs 22.2% compared to patients with diabetic father and paternal aunts/uncles 
respectively in Arabic patients residing in Qatar (Bener et al., 2012).  
Similarly, study in Moroccans has shown that familial aggregation of T2DM was 
prominent and more important in the first-degree relatives than second degree 
relatives (Benrahma et al., 2011). Earlier evidence has shown that first degree 
relatives of individuals with T2DM are three times more likely to develop the disease 
as compared to individuals without positive familial history of diabetes (Florez et al., 
2003). Studies have shown that the concordance rate in monozygotic twins is 70% 
whereas for concordance rate for dizygotic twins has been observed to be 20-30% 
(Hari Kumar et al., 2014). The familial risk for the disease is strong when studies are 
restricted to parents aged 35-69 years old, which is also an indication of environmental 
influence in the disease susceptibility (Almgren et al., 2011). 
Moreover, genome wide association studies have shown that single nucleotide 
polymorphisms (SNPs) of various candidate genes are associated with increased 
susceptibility for T2DM. These genes include proliferator-activated receptor gamma 
(PPAR-γ) (Barroso et al., 2006),  potassium voltage-gated channel subfamily J 
member 11 (KCNJ11) (Schwanstecher et al., 2002), hepatocyte nuclear factor 4 alpha 
(HNF4A) (Hara et al., 2006), transcription factor 7-like 2 (TCF7L2) (Barroso et al., 
2005) and  their association with T2DM risk were reproduced in other studies. 
Furthermore, genome association studies have shown that vitamin D receptor gene 
polymorphisms are associated with T2DM risk among various population, although the 





results are inconclusive. Current study will examine the association of those single 
nucleotide polymorphisms with T2DM risk. 
2.4 Diagnostic criteria for diabetes mellitus. 
Diabetes mellitus may be screened or diagnosed based on HbA1c or glucose criteria, 
either by using the fasting plasma glucose or 2-hr plasma glucose (2-h PG) value after 
75-g oral glucose tolerance test (OGTT). A glucose test is performed on patients who 
are asymptomatic during physical examination or suspicious of either being diabetic 
or suffering from IFG or IGT. If the results comply with the outlined criteria for diagnosis 
of diabetes mellitus, then diagnosis is made. Patients can also be subjected to oral 
glucose tolerance test (OGGT) after an overnight fast (8-12hrs) to detect impaired 
fasting blood glucose levels, impaired glucose tolerance and diagnose diabetes based 
on the values depicted on Table 2.1.  
Table 2.1: Diagnostic criteria for diabetes, IGT and IFG based on ADA and 
WHO. 
 ADA 2014 WHO 2016 
Diabetes 
    FPG 
    2-H plasma glucose 
    HbA1C 
 








    FPG 
    2-h plasma glucose 
 
Not required 
≥7.8 mmol/l or ˂11.1mmol 
 
˂7.0 and 
≥7.8 and ≤11.1 mmol/l 
IFG 
    FPG 
    2-h plasma glucose 
 
5.6-6.9 mmol/l 
If measured; ≤11.1 mmol/l 
 
6.1-6.9 mmol/l and 
˂7.8 mmol/l (if measured) 
 
According to (World Health Organization, 2016), participants with fasting plasma 
glucose levels between (6.1-6.9 mmol/L) are considered to have impaired fasting 
glucose (IFG) and those with 2-hr plasma glucose levels (≥7.8 and ≤11.1 mmol/L) are 
considered to have impaired glucose tolerance (IGT). The latter is diagnosed 
exclusively by using OGGT test. In contrast to ADA, WHO recommend that FPG cut-
point for IFG should remain at 6.1 mmol/l the reason being that lowering the cut-point 





would increase the proportion of people with IGT who have IFG but decrease the 
proportion of people with IFG who also have IGT. Participants with either impaired 
fasting glucose or impaired glucose tolerance are in the prediabetic state. IFG and IGT 
are the two distinct intermediate states that precedes Type 2DM (Rasmussen et al., 
2008). Glycated haemoglobin (HbA1c) greater than 6.5% is also being used to 
diagnose diabetes. 
2.5 Prevalence of type 2 diabetes mellitus (T2DM) in South 
Africa. 
Type 2 diabetes mellitus is the major cause of morbidity and mortality, accounting for 
over 90% of diabetes cases globally. The number of people with type 2 diabetes 
mellitus is increasing globally with 80% of diabetes mellitus cases living in low-and 
middle-income countries (LMICs). In 2014, about 8.5% of adults aged 18 years and 
older had diabetes. This disease caused 1.6 million deaths in 2014 and high blood 
sugar was the direct cause of another 2.2 million deaths in the year 2012.  
The incidence of this disease varies substantially from one geographical region to the 
other due to environmental and lifestyle factors. According to WHO, diabetes mellitus 
will be the seventh leading cause of death in 2030 (Mathers et al., 2006). More recent 
IDF estimates show that 415 million (uncertainty: 340-536 million) people aged 20-79 
years had diabetes in the year 2015 (Ogurtsova et al., 2017). Of that diabetes was 
accountable for 5.0 million deaths and total health expenditure due to diabetes was 
estimated at 673 billion US dollar. About a quarter (75%) of diabetes cases aged 20-
79 were residing in low-and middle-income countries (LMICs). It is projected that the 
number of type 2 diabetic cases will rise to 642 million (uncertainty: interval of 521-
829 million) in 2040. 
Furthermore, (Erasmus et al., 2012) reported a high prevalence of T2DM (28.2%) and 
18.1% of undiagnosed diabetes cases within the mixed ancestry population residing 
in Bellville South, Cape Town, South Africa. These rates are alarming and urgent 
attention is needed to alleviate the burden of diabetes and to implement preventative 
methods for early detection of people who are at an increased risk for the disease.  





2.6 Vitamin D. 
2.6.1 Background. 
Vitamin D is a group of fat-soluble vitamins required for the intestinal absorption of 
calcium and phosphorus. Vitamin D exists in two forms: vitamin D2 (ergocalciferol) and 
vitamin D3 (cholecalciferol). Vitamin D is required for the maintenance of bone health 
and body mineral homeostasis. In children, Vitamin D deficiency causes a condition 
called rickets, which is characterized by poor bone mineralization that leads to soft 
and weakened bones and bone deformities (Holick et al., 2011);(Sahay et al., 2012). 
In adults, vitamin D deficiency causes osteomalacia, which is characterized by 
softened bones, bone pain and muscle weakness (Sahay et al., 2012). The beneficial 
effect of vitamin D was discovered in 19th century when Sir Edward Mellanby of Great 
Britain was concerned with extremely high incidence of rickets in the United Kingdom, 
especially in Scotland. 
Sir Edward assumed that rickets could be caused by dietary deficiency. He further 
went on feeding dogs the Scottish diet, primarily consisting of oatmeal. He kept dogs 
indoors and deprived them of sunlight (Mellanby et al., 1918). Those dogs developed 
rickets which was identical to human disease. Interestingly, he managed to cure the 
disease by feeding dogs cod liver oil and he assumed that cure could be attributed to 
the effect of vitamin A. McCollum and Davis, discovered vitamin A and they found  that 
it prevented xeropthalmia (McCollum et al., 1913). He proved that vitamin A was not 
a  cure for rickets by heating cod liver oil and he found that cod liver oil still cures 
rickets and that preparation was no longer able to prevent xeropthalmia and vitamin A 
deficiency (McCollum et al., 1922). McCollum further concluded that the factor that 
cured rickets is vitamin D, because vitamin A, vitamin B and vitamin C were already 
discovered. 
The best evidence on the health outcomes of vitamin D to date is documented in bone 
health. However, accumulating evidence has suggested a role of vitamin D in non-
skeletal diseases including cancers, autoimmune disorders, infectious diseases, 
cardiovascular disease and type 2 diabetes mellitus (Engelman et al., 2010). However, 
most literature on the non-skeletal health outcomes of vitamin D remains inconclusive. 





2.6.2 Sources of vitamin D. 
Vitamin D may be obtained through diet or supplementation like other vitamins. 
Moreover, vitamin D has a unique characteristic that it can also be synthesized from 
the skin through exposure of the skin to ultra-violet radiation range between 298-315 
nm (Spustová et al., 2004)(Holick et al., 2007). Cutaneous synthesis of vitamin D is 
affected by several factors such as age, skin pigmentation, season, latitude, clothing, 
use of sunscreens and sun exposure (Chen et al., 2007). Dietary sources of vitamin 
D are shown on table 2.2 and they includes fish liver oil, cod liver oil, salmon, sardines, 
tuna, mushrooms and egg yolk (Holick et al., 2007), Many foods are fortified with 
vitamin D, due to limited amount of vitamin D naturally occurring in food products. The 
two main forms of vitamin D are derived from different sources: ergocalciferol is 
derived from the irradiation of ergosterol found in the membranes of yeast and fungus  
(Bikle et al., 2014) whereas cholecalciferol is derived from conversion of the vitamin D 
skin precursor 7-dehydrocholesterol (DHRC7) upon exposure to UVB radiation (Holick 
et al., 2007). Furthermore, a meta-analysis study has found that supplementation with 
vitamin D3 is more effective for raising serum 25(OH)D than vitamin D2 (Tripkovic et 
al., 2012). 
Table 2.2: Dietary sources of vitamin D. 
40 IU is equivalent to 1 ug/l, Adopted from (Holick et al., 2007) 
Dietary source Vitamin Dᵃ content (IU) 
Salmon: Fresh wild 
               Fresh farmed 
               Sardines canned 
               Tuna canned 
               Mackerel canned 
Shiitake mushrooms: Fresh 
                                     Canned 
600-1000 Vitamin D₃ 
100-250 Vitamin D₃ or D₂ 
300 Vitamin D₃ 
236 Vitamin D₃ 
250 Vitamin D₃ 
100 Vitamin D₂ 
1600 Vitamin D₂ 
Egg, hard-boiled 20-Vitamin D₂ 
Supplements: Ergocalciferol 
                         Cholecalciferol 
                         Multivitamin 
50 000/ Capsule 
400, 800, 1000, 2000 etc. 
400, 800 and 1000 Vitamin D₃ or D₂ 





2.6.3 Metabolism of vitamin D. 
Vitamin D obtained from both cutaneous synthesis, diet and supplementation is not 
active, hence it must first undergo series of hydroxylation steps to be converted to the 
biologically active form. Vitamin D circulates in the blood bound to vitamin D binding 
protein (VDBP), which is a primary transporter for vitamin D and its metabolites (Wang 
et al., 2014) . VDBP then transport vitamin D to the liver where it undergoes first 
hydroxylation to 25-Hydroxyvitamin D or 25(OH)D catalysed by enzyme cytochrome 
P450 (CYP2R1) enzyme. Serum 25(OH)D is a major circulating metabolite of the 
vitamin D used to determine patients’ vitamin status (DeLuca et al., 2004); (Holick et 
al., 2007). VDBP further carries hydroxylated vitamin D to the kidneys where it is 
converted to an active form 1.25-(OH)2D by  enzyme cytochrome P450 (CYP27B1) or 
1α-hydroxylase (Zella et al., 2008) However, extra-renal tissues such as dendritic and 
macrophage cells can convert 25(OH)D to 1.25-(OH)2D3, due to the presence of 
CYP27B1 enzyme on their receptors (Van Etten et al., 2005). CYP27B1 is primarily 
increased by elevated PTH levels in the circulation in response to low calcium levels , 
(Bouillon et al., 2006) and it is decreased by elevated fibroblast growth factor 23 
(FGF23) which regulate phosphate levels in circulation and thus indirectly suppressing 
production of 1.25-(OH)2D3 and by direct effects on PTH gland (Bai et al., 2003).1.25-
(OH)2D3 exerts all biological effects of vitamin D (Holick et al., 2009). But, its levels do 
not correlate with overall vitamin D status, hence is not clinically useful  for assessing 
patients vitamin D status (Holick et al., 2007).  
2.6.4 Vitamin D Binding protein (VDBP). 
Vitamin D binding protein (VDBP) is a single glycoprotein, member of albumin and α-
fetoprotein gene family. This glycoprotein is secreted from the liver and its 
concentration in healthy individuals ranges from 300-600µmol/l (Blanton et al., 2011), 
it has a serum short half-life of 2.5-3 days. The total circulating metabolites of vitamin 
D (about 85-90%) binds with high affinity to the VDBP (Powe et al., 2011), and about 
10-15% is bound to albumin whereas about 1% is circulating in free form. VDBP 
synthesis is  oestrogen dependent thus is significantly increased during pregnancy 
and oestrogen therapy (Heijboer et al., 2012). Also, VDBP levels are significantly 
reduced in patients with chronic liver disease, kidney disease and reduced in patients 
with malnutrition (Sinotte et al., 2009).  





VDBP exerts other functions such as macrophage activation, binding of fatty acids and 
clearance of actin filaments due to its actin binding domain (Speeckaert et al., 2006). 
VDBP is encoded by the group-specific component (Gc) gene, a member of the 
multigene cluster that includes albumin (ALB) and α-fetoprotein (AFP) genes family, 
located on chromosome 4q11-q14 (Speeckaert et al., 2006). VDBP has three common 
alleles (Gc1F, Gc1S and Gc2) and more than 120 rare variants, defined by genetic 
polymorphisms rs7041 and rs4588 (Braun et al., 1992). Populations of African 
ancestry have high Gc1F allele frequency Gc1F, whereas Caucasians have markedly 
high Gc2 allele frequency (Speeckaert et al., 2006). Moreover, certain VDBP variants 
are associated with low serum 25(OH)D. The Gc1F-1F has the highest affinity to bind 
25(OH)D compared to Gc2-2 and is associated with high serum 25(OH)D (Braithwaite 
et al., 2015). 
2.6.5 Parathyroid Hormone (PTH). 
Parathyroid hormone (PTH) is a small peptide hormone secreted from parathyroid 
glands at the back of the neck in response to low calcium levels in the circulation 
(Lombardi et al., 2011). It plays a vital role in bone mineral homeostasis by regulating 
and maintaining calcium, phosphorous and activating vitamin D to its active form or 
1.25-(OH)2D3 (Kumar et al., 2011).  In state of low calcium levels, PTH stimulates the 
reabsorption of calcium from the bones and kidneys. PTH serves to increase the 
activity of CYP27B1 to enhance conversion of 25(OH)D to 1.25-(OH)2D3  and decrease 
the activity of 24-Hydroxylase which inhibit production of 1.25-(OH)2D3 (Christakos et 
al., 2010). Furthermore, 1.25-(OH)2D3 may also regulate the activity of calcium sensing 
receptors (CaSR) which maintains calcium homeostasis through regulation of  PTH 
secretion and renal tubular calcium reabsorption in response to low calcium levels in 
the circulation (Magno et al., 2011).  
CaSR is a G coupled protein receptor (GCPR) expressed primarily on the PTH gland, 
kidney tissues and is also expressed in other tissues including, thyroid gland, intestine, 
brain and bones (Ward et al., 2012). PTH synthesis is inhibited by high calcium levels 
(hypercalcaemia) and high 1.25-(OH)2D3 in the circulation. Abnormal secretion of PTH 
is seen in patience with primary hyperparathyroidism, condition that leads to 
hypercalcaemia (Felsenfeld et al., 2007). Also, high PTH secretion is seen in patients 
with secondary hyperthyroidism in response to low calcium levels due to vitamin D 
deficiency or chronic kidney disease (Felsenfeld et al., 2007). 





2.6.6 Factors affecting vitamin D levels. 
2.6.6.1 Cutaneous synthesis. 
Several factors influences cutaneous synthesis of the vitamin D, and these include 
age, skin pigmentation, season, latitude, clothing, use of sunscreens sun exposure 
(Chen et al., 2007). Evidence showed that older age is associated with decreased 
vitamin D synthesis as the skin thickness decreases linearly after the age of 20 years. 
Cutaneous synthesis of vitamin D in the skin is the function of skin pigmentation and 
of solar zenith angle which depends on latitude, season and time of the day (Chen et 
al., 2007). Adequate cutaneous synthesis of vitamin D₃ is met when the skin is 
exposed to UVB light with photon energy range (290-315nm).  
Emerging evidence from observational studies showed that serum 25(OH)D levels 
differ according to age (Maeda et al., 2013), gender, BMI and season. At latitudes far 
from the equator during the winter months there is inadequate amount of UVB from 
the sunlight to allow cutaneous synthesis of 25(OH)D and these observations were 
confirmed by studies conducted in North America (Holick et al., 1994); (Webb et al., 
1988). On the contrary, data from meta-analysis of cross-sectional studies on 
25(OH)D globally showed no changes in 25(OH)D levels with latitude after adjusting 
for age, gender and ethnicity (Hagenau et al., 2009).  
The seasonal variation in serum vitamin D among different ethnic groups from different 
countries is shown in Table 2.3. In addition, evidence on seasonal variation in serum 
vitamin D levels is thus convincing since majority of the studies reported low serum 
vitamin D levels in winter (Kull et al., 2009); (Unger et al., 2010); (Martineau et al., 
2011), although in some of the warm countries lower levels have been reported in 
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2.6.6.2 Genetic factors. 
Certain genes involved in vitamin D metabolism are thought to influence the variability 
in the concentrations of 25(OH)D in patients of all population groups (Wang et al., 
2010). Emerging evidence from genome wide association studies revealed that single 
nucleotide polymorphisms (SNPs) of the VDBP affect 25(OH)D concentrations. 
Variant alleles of other genes such as NADSYN1/DHRC7 that encodes for 7-
dehydrocholesterol, were significantly associated with low serum 25(OH)D in Chinese 
population. Moreover, another study revealed that variant allele Gc and CYP2R1 
polymorphisms were significantly associated with low 25(OH)D in Hispanic women 
and non-Hispanic white (Wang et al., 2014). 
2.6.7 Definition and diagnosis of vitamin D deficiency. 
Vitamin D deficiency is considered a major public health problem worldwide, as it is  
associated with increased risk for both skeletal and non-skeletal health outcomes  
including cancer, autoimmune disorders, infectious diseases, T2DM and CVDs 
(Engelman et al., 2010). Diagnosis of vitamin D deficiency is based on serum 25(OH)D 
levels which reflects both vitamin D intake and endogenous production (Holick et al., 
2007). Institute of Medicine (IOM) released new guidelines for recommendations of 





25(OH)D for dietary reference intakes (DRIs) for calcium and vitamin D, thus updating 
the 1997 DRIs report (Ross et al., 2011). 
IOM stated that as defined by skeletal health, individuals with serum 25(OH)D below 
16 ng/ml are at increased risk, whilst those with 25(OH)D levels between (16-20 ng/ml) 
are potentially at risk and those with 25(OH)D above 20 ng/ml have sufficient vitamin 
D. IOM concluded that 20 ng/ml of 25(OH)D adequately covered the requirements of 
at least 97.5% of adult population in relation to bone health. Based on Endocrine 
Society Practice guidelines, vitamin D deficiency is defined as serum 25(OH)D below 
20 ng/ml (Holick et al., 2011). Definition of vitamin D deficiency was based on (i) the 
elevation of PTH when 25(OH)D levels drops below 20ng/ml, (ii) reduction in PTH 
levels among elders receiving 800IU vitamin D dose compared to 400IU and (iii) 
increased intestinal absorption of calcium when 25(OH)D is above 30ng/ml. However, 
studies have showed that the use of PTH for defining optimal vitamin D status has 
limitations, due to PTH levels being associated with increase in age, obesity and renal 
dysfunction. Data from the National Health and Nutrition Examination survey 
(NHANES) III have showed that change in the diagnosis of vitamin D deficiency from 
<16ng/ml to <20ng/ml increased prevalence of vitamin D deficiency from 2% to 14% 
(Saintonge et al., 2009). 
2.6.8 Vitamin D receptors (VDR) polymorphisms. 
Vitamin D receptor (VDR) is a steroid/thyroid hormone receptor family that functions 
as a transcriptional activator of many genes. Active vitamin D mediates its biological 
function on target tissues through binding to VDR (Haussler et al., 2011). Upon binding  
VDR and after subsequent phosphorylation steps by kinase cascades, the VDR 
undergoes a conformational change that facilitates its capacity to binding the retinoid 
X receptor (RXR) thus forming heterodimer, which further interacts with the vitamin D 
responsive (VDREs) in the promoter region of target genes thus modifying their 
expression (Haussler et al., 2011); (Zella et al., 2003). 
The VDR gene is located on the negative strand of chromosome 12 positioned on the 
longer arm of the chromosome (12q11.1). VDR gene consists of 14 exons with 
extensive promoter region capable of generating multiple specific transcripts 
(Uitterlinden et al., 2004). VDRs are widely distributed in more than 38 tissues, where 
it controls vital genes involved in bone metabolism, oxidative damages, chronic 





diseases and inflammation (Haussler et al., 2008). There are four common single 
nucleotide polymorphisms (SNPs) of the VDR gene, which are extensively studied 
namely: Fok1 (rs2228570), Bsm1 (rs154440), Apa1 (rs7975232) and Taq1 (rs731236) 
among other identified polymorphisms (Uitterlinden et al., 2004).  
Fok1 SNP is located at exon 2 within the 5’ end of the VDR gene near the promoter 
region and (Bsm1 and Apa1) SNPs are located closely in intron 8 and Taq1 SNP at 
exon 9 at the 3’ end of the VDR gene respectively, they are genetically linked (Naito 
et al., 2007). Among four loci on the VDR gene, the Fok1 SNP is known to affect the 
structure of VDR protein produced (Wang et al., 2012). This is due to the  variant T (f) 
allele of the Fok1 SNP which encodes 427 amino acid proteins whereas F allele 
encodes 424 amino acid proteins (Uitterlinden et al., 2004). Consequently, the shorter 
VDR variant protein seem to function effectively and has a higher binding affinity to 
1.25-Dihydroxyvitamin D₃ (Reis et al., 2005). 
VDR gene Bsm1, Apa1 and Taq1 SNPs irrespective of their loci on the VDR gene, 
were reported to have no effect in altering VDR protein structure (Uitterlinden et al., 
2004). These SNPs within the VDR gene are associated with altered gene expression 
or gene function (van Etten et al., 2007), thus the allelic variations in the VDR gene 
may contribute to genetic predisposition of certain diseases (Palomer et al., 2008). In 
addition, VDR gene is considered as a particular good candidate gene for susceptibility 
to T2DM, due to its involvement in the metabolic pathway of T2DM (Nosratabadi et 
al., 2010). 
2.7 Role of vitamin D in the pathogenesis of T2DM 
T2DM is a chronic metabolic disease characterized by increased insulin resistance, 
hyperglycaemia and pancreatic β-cell dysfunction. Studies have shown that physical 
inactivity, poor nutrition practices and obesity may contribute significantly to the 
development of T2DM (Moreira et al., 2010). However, the actual aetiopathogenesis 
of T2DM is unknown. Increasing evidence suggests that vitamin D deficiency may play 
a role in the pathogenesis of T2DM. This is due to the presence of VDR and VDBP on 
the pancreatic β-cells (Palomer et al., 2008). Vitamin D deficiency has been shown to 
alter insulin synthesis and insulin secretion in both human and animal models. 
However, vitamin supplementation restores insulin secretion and decreases insulin 
resistance and plasma glucose levels (Palomer et al., 2008);(Moreira et al., 2010). 





Additionally, low vitamin D status has been associated with glucose intolerance and 
occurrence of T2DM in several populations. The proposed mechanisms in which 
vitamin D deficiency predisposes patients to T2DM may be either through direct action 
on VDR activation or indirectly via calcium hormones and inflammation (Thorand et 
al., 2011);(Sung et al., 2012). 
Vitamin D is postulated to affect glucose tolerance (Palomer et al., 2008), and reduced 
concentrations have been associated with pancreatic β-cell dysfunction, insulin 
receptor down regulation and insulin resistance (Chiu et al., 2004). Evidence state that 
vitamin D and its metabolites may play a role in preventing T2DM by increasing insulin 
sensitivity and secretion and overall pancreatic β-cell function (Christakos et al., 2003). 
There is greatly increased prevalence of T2DM in obesity (Nguyen et al., 2008) and it 
has been reported that obesity is one of the risk factors for vitamin D deficiency in 
diverse populations (Iqbal et al., 2017). Obesity is a state of chronic low-grade 
inflammation and adipose tissues are major sources of inflammation with the 
infiltration of macrophages as the primary source of cytokines in obese individuals 
(Bellia et al., 2013) (Xu et at., 2003) (Stienstra et al., 2007). An increase in acute phase 
proteins such as CRP, pro-inflammatory cytokines and mediators associated with 
endothelial dysfunction has been reported in T2DM. Vitamin D has anti-inflammatory 
effects, which reduces chronic inflammation and thus improving insulin sensitivity in 
patients with obesity low vitamin D levels have been shown to be associated with a 
rise in CRP and increased proinflammatory cytokines such as IL-6 and TNFα (Bellia 
et al., 2013), which impairs insulin signalling through different mechanisms, thus 
leading to increased systemic inflammation, insulin resistance and hyperglycaemia. 
Moreover, vitamin D supplementation has been shown to reduce inflammatory 
cytokines such as IL-6 and TNFα which play significant role in inducing insulin 
resistance (Schleithoff et al., 2006). 
2.8. Association studies among vitamin D, vitamin D binding 
protein and vitamin D receptor polymorphisms. 
2.8.1 Association between vitamin D and T2DM. 
Previous studies have demonstrated the role of vitamin D deficiency/insufficiency in 
abnormal glucose metabolism as well as in T2DM (Palomer et al., 2008). Study 
performed in type 2 diabetes patients residing in the area of Arens and Pireaus in 





Greece showed that vitamin D levels were very low in diabetic cases than controls and 
lower vitamin D correlated negatively with glycosylated haemoglobin levels even after 
adjustment for confounders (Kostoglou-athanassiou et al., 2013). In addition, vitamin 
D deficiency has been considered as a possible risk factor for the development of 
insulin resistance and T2DM by affecting either insulin sensitivity or β-cell function or 
both (Deleskog et al., 2012) ; (Forouhi et al., 2008). 
The proposed mechanisms in which vitamin D deficiency predisposes to T2DM may 
be either through direct action on vitamin D receptor activation or indirectly via calcium 
hormones and inflammation (Thorand et al., 2011); (Sung et al., 2012). A recent 
association study showed that in patients with established T2DM and in the general 
population, low 25(OH)D levels are associated with higher fasting glucose, insulin 
resistance and metabolic syndrome (Lips et al., 2016). There is also epidemiological 
evidence that has shown a positive correlation between circulating 25(OH)D and 
insulin sensitivity, further demonstrating that vitamin D deficiency may predispose to 
glucose intolerance, altered insulin secretion and T2DM (Pittas et al., 2010). This data 
was corroborated by the results of an earlier study which evaluated the association 
between 25(OH)D and metabolic syndrome (Lu et al., 2009). In this study there was 
an inverse association of low 25(OH)D with fasting insulin (β=-0.06, p=0.01) and 
HOMA-IR (β=-0.06, p=0.004) only in overweight subjects.  
In a study from Korea, low 25(OH)D was associated with fasting glucose, and OR for 
diabetes in individuals with serum 25(OH)D < 25, 25-<50 and 50-<75 compared to 
individuals with serum levels  ≥ 75nmol/L were as follows 1.30 (0.91-1.84), 1.40 (0.99-
1.98) and 1.73 (1.09-2.74), respectively, p trend <0.001 (Choi et al., 2011). A recent 
cross-sectional study showed a negative correlation between low serum 25(OH)D with 
insulin resistance (HOMA-IR: r = -0.200; p=0.03) and fasting plasma glucose (r= -2.95; 
p= 0.001) but not with BMI (Clemente-Postigo et al., 2015). Furthermore, this data 
indicates an association of low serum 25(OH)D and diabetes independently of BMI. 
On the contrary, the 3rd NHANES data showed that OR for diabetes varied inversely 
across 25(OH)D quartiles for Non-Hispanic Whites and Mexican Americans (OR 0.25 
[CI 0.011-0.60] and 0.17 [0.08-0.37], respectively) for those in the highest quartile 
compared to the lowest (≥81.0 nmol/L vs ≤43.9nmo/L), respectively, such was not 
observed in Non-Hispanic Blacks (Scragg et al., 2004). In addition, HOMA-IR was 





inversely associated 25(OH)D in Non-Hispanic Whites (p=0.058) and Mexican 
Americans (p=0.0024) but not in Non-Hispanic Black. It was concluded that lack of 
inverse association in the Non-Hispanic Black group may reflect decreased sensitivity 
to vitamin D/or related hormones such as PTH. Another study showed an inverse 
association of baseline 25(OH)D with T2DM, but the relationship became insignificant 
after adjusting for BMI (Grimnes et al., 2010). A more recent cross-sectional study in 
a Bangladeshi population showed that serum vitamin D levels were significantly low in 
T2DM patients compared to controls (21.30 ± 0.88 vs 43.41 ± 2.52, p<0.001), 
respectively (Rahman et al., 2017). In this study there was a significant negative 
correlation between serum vitamin D levels and fasting glucose in type 2 diabetes 
patients (r =−0.25, p < 0.05).  
2.8.2 Association between vitamin D binding protein (VDBP) and T2DM. 
Studies demonstrated a positive correlation between serum VDBP concentrations and 
Active vitamin D (1.25-Dihydroxyvitamin D₃) concentrations (Lauridsen et al., 2005); 
(Ponda et al., 2014). Moderate association of the VDBP polymorphisms with increased 
susceptibility to T2DM in Asians have been shown, but not in Caucasians (Wang et 
al., 2014). Vitamin D binding proteins polymorphisms may predispose to T2DM, 
moreover VDBP polymorphism 1S and 2 were associated with higher fasting plasma 
insulin in Japanese subjects (Lips et al., 2016).  
2.8.3 Association between vitamin D receptor polymorphisms and 
T2DM. 
VDR is expressed in several tissues including those involved in the regulation of 
glucose metabolism such as muscles and pancreatic β- cells (Palomer et al., 2008). 
Moreover, Vitamin D modulates the expression of the insulin receptor genes, insulin 
secretion, and exert its action on target tissues by binding to the nuclear VDR (Al-
Daghri et al., 2012). As vitamin D modulate insulin secretion it is thus possible that 
genetic variations in the VDR gene may contribute to development of type 2 diabetes 
mellitus (Palomer et al., 2008).  Correlation between VDR polymorphisms and T2DM 
related metabolic parameters such as glucose intolerance, insulin sensitivity, higher 
fasting glucose and low vitamin D levels have been reported (Uitterlinden et al., 2004). 
For example, earlier studies reported that polymorphisms within intron 8 and exon 9 
of the VDR affect expression of the protein (Nosratabadi et al., 2010), thus Apa1, Bsm1 





and Taq1 are important in the pathogenesis of T2DM through their effects on the VDR 
gene expression level. These three SNPs (Bsm1, Apa1 and Taq1) are in strong 
linkage disequilibrium (Uitterlinden et al., 2004). 
A study in healthy Bangladeshi Asian population with prevalent vitamin D deficiency 
showed an association between Apa1 polymorphism (aa) and lower insulin secretion 
(Hitman et al., 1998). In the Rancho Bernard study, VDR gene Apa1, Bsm1 and Taq1 
SNPs were examined and frequency of aa genotype of Apa1 SNP was marginally 
higher in T2DM patients. Also fasting plasma glucose and prevalence of glucose 
intolerance was higher in non-diabetic Caucasians with aa genotype compared those 
with AA genotype and the bb genotype of the Bsm1 SNP was associated with insulin 
resistance (Oh et al., 2002). Similarly, (Ogunkolade et al., 2002) reported positive 
association between Bsm1 (bb genotype) and Taq1 (TT genotype) polymorphisms 
with reduced insulin secretory capacity within the same population. Another study 
examined association of fasting glucose, low physical activity (PA) and Bsm1 SNP 
(Ortlepp et al., 2003), they found that males with low PA and carriers of BB genotype 
of the Bsm1 had elevated fasting glucose. However, such an effect was not observed 
in those with high PA. Additionally, the VDR gene polymorphisms Bsm1 and Taq1 
were associated with an increased susceptibility for T2DM in Saudi Arabian subjects 
(Al-Daghri et al., 2012) 
A cohort study from Brazil reported that the variant genotype ff of Fok1 polymorphism 
was significantly associated with increased insulin resistance index (HOMA-IR), whilst 
the variant Ff was significantly associated with increased β-cell function (HOMA-β) 
and iPTH in patients with the metabolic syndrome (Schuch et al., 2013). However, in 
patients without the metabolic syndrome the variant genotypes Ff and ff were 
significantly associated with higher triglycerides levels and lower HDL-C. For Bsm1 
only the variant genotype bb was significantly associated with lower 25(OH)D. Of note, 
a meta-analysis of cross-sectional studies showed that Fok1 polymorphisms were 
associated with increased risk for T2DM (f vs. F: OR 1.30, 95% CI:1.17-1.45, p< 
0.001), especially in East Asians (f vs. F: OR 1.36, 95% CI:1.21-1.54, p< 0.001), while 
Bsm1 was associated with T1DM (Wang et al., 2012), and no association was 
observed for Apa1 and Taq1 polymorphisms with either T1DM or T2DM. These 
findings were corroborated by a study conducted in the Kashmir valley ethnic 
population group which showed that Fok1 polymorphisms are significantly associated 





with increased risk for T2DM and whereas Bsm1 was not (Malik et al., 2017). Also, 
lower vitamin D deficiency in this population was inversely associated with HbA1c 
levels. 
Additionally,  a study in an Emirati population with T2DM showed that allelic variant G 
of the Fok1 and T of the Bsm1 were associated with increased odds ratios for T2DM 
{(OR= 1.843, 95%CI=1.288-1.637,p=0.0007, and OR= 1.45,CI=1.032-2.036, p=0.031, 
respectively)} and consequently, the AG and GG genotypes of the Fok1 and TT 
genotypes of Bsm1 were associated with increased risk for T2DM {(OR=2.488, 95% 
CI=1.178-5.256, p=0.015; OR=3.482, 95% CI=1.678-7.224, P=0.0005; OR=1.921, 
95% CI=1.009-3,658, P=0.045, respectively)} respectively (Al et al., 2018). More 
recent study evaluated the association between Taq1 polymorphisms in VDR gene 
and T2DM in obese Iraq population (Al-darraji et al., 2017). This study showed that 
variant genotypes TT or Tt of the Taq1 SNP were significantly associated with 
increased risk for diabetes in patients with T2DM, even after adjusting for HbA1C, BMI, 
sex, diabetes duration and concurrent dyslipidaemia. Another study which examined 
Egyptian patients with T2DM with metabolic syndrome showed that variant genotype 
ff of  Fok1 was significantly associated with higher insulin levels, insulin resistance, IL-
6 levels, waist circumference and BMI, whereas in those without metabolic syndrome, 
the variant genotype ff was associated with abnormal lipids profile (elevated TG, TC 
and LDL-C and lower HDL-C), and Bsm1 SNP was associated with vitamin D 
deficiency in both groups (Mackawy et al., 2014). 
Similarly, in Moroccans patients with prevalent vitamin D deficiency, the variant 
genotype ff of the Fok1 was associated with reduced risk for development of T2DM 
(OR=0.35,CI=0.14-0.83 p=0.018) whereas, Bsm1, Apa1 and Taq1 were not (Abdeltif 
et al., 2014). Moreover, the variant ff of the Fok1 SNP was significantly associated 
with abnormal lipid (elevated TC, TG and LDL-C and lower HDL-C, p<0.05). Only Apa1 
polymorphisms was associated with increased systolic blood pressure. Results from 
another study by (Al-daghri et al., 2014) showed that variant genotype CT and 
dominant model CT+TT of Bsm1 were significantly associated with increased risk for 
T2DM (OR=1.7, 95% CI=1.2-2.4, p=0.007; OR=1.5, 95% CI=1.1-2.2, p=0.01, 
respectively) and further revealed that variant allelic C of Fok1 was significantly 
associated with reduced risk for development of T2DM (OR=0.73, 95% CI=0.56-0.95, 
p=0.02). All of the above-mentioned studies are summarized on table 2.4 below. 





Table 2.4: Association between VDR polymorphisms and T2DM. 
Gene SNP SNP 
genotype 














Increased β-cell function Brazilians with MetS (Schuch et al., 
2013) 
increased risk for T2DM Emirati population with 
T2DM 
(Al et al., 2018) 
Reduced risk for T2DM Saudi Arabian 
population 
(Al-daghri et al., 
2014) 
Ff /AG Increased risk for T2DM Emirati population with 
T2DM 






Increased HOMA-IR Brazilians with MetS. (Schuch et al., 
2013) 
Higher insulin levels, insulin 
resistance, IL-6 levels, waist 
circumference and BMI 




(Mackawy et al., 
2014). Elevated TG, TC and LDL-C 
and lower HDL-C 
T2DM Egyptian patients 
without MetS 
Reduced risk for 
development of T2DM, 
elevated TC, TG and LDL-C 
and lower HDL-C 
Morocco patients with 
prevalent vitamin D 
deficiency 












Lower insulin secretion Bangladeshi Asian with 
prevalent vitamin D 
deficiency 
(Hitman et al., 
1998) 
Higher fasting plasma 
glucose and prevalence of 
glucose intolerance 
Rancho Bernard study 
(elderly non-diabetic 
Caucasian patients) 








 Increased risk for T2DM Saudi Arabian  
TT/AA Increased risk for T2DM Obese Iraq patients (Al-darraji et al., 
2017) 






Tt/AG Increased risk for T2DM Obese Iraq patients (Al-darraji et al., 
2017) 
 
There is great controversy on the association of VDR polymorphisms and their 
involvement in the pathogenesis of T2DM. Fok1, Bsm1, Apa1 and Taq1 
polymorphisms were not associated with risk for T2DM in Polish population with and 
without T2DM (Cyganek et al., 2006). Similarly, (Banerjee et al., 2009) showed no 
association of the Fok1, Bsm1 and Taq1 polymorphisms with increased risk for T2DM 
in North Indians. Moreover,  Apa1 and Taq1 SNPs were not associated with risk for 
T2DM in Turkish population (Dilmec et al., 2010). The allele f of the Fok1 SNP encodes 
427 amino acid proteins whilst the F allele encode 424 amino acid proteins. Studies 
have reported that shorter VDR variant protein seems to function more effectively and 
have increased affinity to bind active vitamin D (Reis et al., 2005), subsequently 





relatively higher active vitamin D in turn can reduce the risk of developing T2DM by 
enhancing pancreatic β-cell function and improve insulin resistance (Pittas et al., 
2007); (Ozfirat et al., 2010).  
Data from various animal and epidemiological based studies have indicated that 
vitamin D deficiency is a risk factor for the development of T2DM both in animal and 
humans (Palomer et al., 2008); (Pittas et al., 2010). Various research groups have 
examined the association of VDR gene polymorphisms (Fok1, Bsm1, Apa1 and Taq1) 
in relation to increased susceptibility for T2DM in different ethnic groups, however the 
results are inconsistent. Discrepancies among these reports could be attributed to 
genetic differences in the populations that were studied or their differential exposure 
to environmental factors. There is no available data on the association of vitamin D 
status, vitamin D receptor polymorphisms and T2DM in the mixed ancestral population 
of Bellville South, Cape Town, South Africa that has been reported to have a high 
prevalence of diabetes (Erasmus et al., 2012). Therefore, the current study aims to 
examine the relationship between vitamin D, vitamin D binding proteins and vitamin D 
receptor polymorphisms (Fok1, Apa1 and Taq1) in diabetic and non-diabetic patients 
within the mixed ancestral population. 





Chapter 3 Purpose of the study 
3.1 Research question. 
What is the relationship between vitamin D, vitamin D binding proteins and VDR 
polymorphisms in (T2DM) in the mixed ancestral population of South Africa as 
investigated in Bellville South, a suburb of Cape Town. 
3.2 Problem statement. 
T2DM a multifactorial disease caused by interaction of genetics and environmental 
factors. The condition is characterized by hyper-glycemia and insulin resistance due 
to β-cell dysfunction or abnormal insulin action. Genetic predisposition of the disease 
has led to identification of several genes involved in its metabolic pathway. Therefore, 
it is important to understand the mechanisms underlying the development of the 
disease and discovery of risk factors which may contribute to its pathogenesis so that 
early detection of the disease can be made. One of the environmental risk factors for 
T2DM is vitamin D deficiency as it has been shown to modulate insulin sensitivity and 
secretion from the pancreatic β-cells. Secondly, presence of the vitamin D receptors 
on the pancreatic β-cells have suggested the role of vitamin D in glucose regulation. 
The prevalence of T2DM is very high (28%) within the mixed ancestry population 
group of Bellville south, Cape Town, South Africa. Additionally, this population has 
been reported to have high prevalence of obesity and hypertension. However, 
genetics that predispose this ethnic group to T2DM are poorly understand. Vitamin D 
receptor gene is considered as a particular good candidate gene for susceptibility to 
T2DM. Hence, variants of the VDR may possibly play a role in predisposing individuals 
to T2DM. Association between VDR gene variants and susceptibility has been shown 
in various ethnic population groups especially of European origin. There is limited data 
in African populations although the results are often inconclusive. The present study 
was undertaken to investigate the association between vitamin D, vitamin D binding 
proteins and VDR polymorphisms in T2DM and non-diabetic patients. 
3.3 Hypothesis. 
The association between Vitamin D, Vitamin D Binding proteins and Vitamin D 
Receptor polymorphism in diabetic and non-diabetic patients may contribute and be 





associated with the high prevalence of T2DM in the mixed ancestry population of 
South Africa.  
3.4 Aim. 
To determine the association between vitamin D, vitamin D Binding proteins and VDR 
polymorphism in diabetic and non-diabetic patients. 
3.4.1 Objectives. 
• To assess vitamin D status by measuring serum 25(OH)D levels. 
• To measure vitamin binding proteins levels using ELISA kit. 
• To determine VDR gene polymorphisms using real-time polymerase chain 
reaction (RT-PCR). 
• To assess the relationship between vitamin D, vitamin D binding proteins and 
VDR-polymorphisms.





Chapter 4  Methodology. 
This chapter focuses on the methods used in the present study. All the methods used 
are validated and have thus been previously used by other research groups. The 
analytical methods include determination of the serum vitamin D “25(OH)D” 
concentrations using a paramagnetic-particle chemiluminescence immunoassay on 
the Beckman DXI test, serum vitamin D binding protein (VDBP) concentrations 
determination using Human Vitamin D Binding protein Quantikine ELISA kit and 
Genomic DNA extraction using salting-out method and genotyping of the VDR single 
nucleotide polymorphisms using TaqMan SNP Genotyping Assays on real-time PCR 
platforms. 
4.1 Study design. 
This is a cross-sectional descriptive study employing quantitative methods. The study 
aims to investigate the relationship between vitamin D, vitamin D-Binding proteins and 
VDR polymorphisms in diabetic and non-diabetic subjects. 
4.2 Study population. 
The current study uses data from the Cape Town Vascular and Metabolic Health 
(VMH) study, which is an extension of the Cape Town Bellville South Study (Davison 
et al., 2017)  Baseline examinations for the VMH study were conducted between 2014 
and 2016. The larger study has received ethics clearance from The Cape Peninsula 
University of Technology Health and Wellness Sciences Research Ethics, reference 
number CPUT/HW-REC 2015/H01. The current study comprised of 1603 participants 
(387 males and 1216 females). 
4.3 Inclusion criteria. 
• In this study age group criteria were limited to participants aged 20 years or 
older 
• All participants gave informed written consent to participate in the study. 





4.4 Exclusion criteria. 
4.4.1 Pregnancy. 
Pregnancy and consumption of oral contraceptives pills increases the levels of vitamin 
D binding proteins and vitamin D in the serum (Møller et al., 2012), (Møller et al., 2013). 
Hence, samples from pregnant women and oral contraceptive pills users were 
excluded for the current study. 
4.4.2 Chronic liver disease 
Serum vitamin D binding proteins and vitamin D levels are decreased in patients with 
chronic liver diseases, due to decreased synthesis of vitamin D binding proteins and 
albumin from the liver and. Thus, first hydroxylation of vitamin D will be reduced. 
Hence, samples from patients with chronic liver disease were excluded in the current 
study. 
4.4.3 Renal diseases. 
Accumulating data have shown that low serum vitamin D levels are common in 
patients with chronic kidney diseases at all stages (Chun et al., 2014). In addition, an 
alteration in the megalin-dependent uptake of DBP in the kidney in CKD would be 
expected to reduce intracrine conversion of 25(OH)D to active 1.25(OH)2D3. Thus, 
resulting in complications such as renal osteodystrophy. Hence, samples from patients 
with renal disease were excluded in the current study. 
4.5 Sample size. 
The sample size needed for this study has been calculated using the following formula 
and the estimated prevalence of diabetes within the Bellville South community which 
was reported as 28% by (Erasmus et al., 2012) 
The formulae used is:  
n = z2(pq)/e2 
Where: 
n = the sample size 
z = standard error associated with the chosen level of confidence (1.96) 
p = estimated percent in the population 





q = 100-p 
e = acceptable sample error (5%) 
Calculation 
n = z2(pq)/e2 
n = {1.962(28.2 * (100-28.2)}/52 
n = 311 
Therefore, sample size needed is 311 participants. 
4.6 Ethical considerations 
Ethics clearance for the current study was sought from Stellenbosch University Health 
Research Ethics Committee (HREC), ethics reference number 0719 as well as from 
the Cape Peninsula University of Technology, Faculty of Health and Wellness 
Sciences Research Ethics reference number CPUT/HW-REC 2015/H01. Samples for 
the current study were selected from stored samples from the main study from 
participants who gave voluntary informed consent. Participants for the main study 
were informed about their rights and voluntary participation has been explained to 
them and that they could withdrew from the study at any stage. All information was 
kept confidential, same as the current study.  
4.7. Anthropometric measurements. 
4.7.1 weight.  
The Omron Body Composition Monitor (BF511: Omron, Japan) was used to measure 
participants’ weight in kilograms (kg). Participants were weighed in light clothing and 
barefooted. The weight of all participants, except wheelchair bound or those who had 
impaired posture were measured. The participant would stand on the centre of the flat 
surface of the scale after it had been zeroed. Hands were placed on the sides and 
ensuring that subject’s weight was evenly distributed, the reading was taken (Tolonen 
et al., 2002). Readings less than 0.5 kg were rounded off to the nearest lower kilogram 
while those above 0.5 kg were rounded off to the nearest higher kilogram. The body 
mass index (BMI) was calculated by dividing the weight and height squared 
[weight/height2] (kg/m2).  






The Omron Body Composition Monitor (BF511: Omron, Japan) was used to measure 
height of the participants. The stadiometer was used to measure body height to the 
nearest 0.1 centimetre (cm). The participant had to stand upright on the flat surface of 
the stadiometer without shoes (Tolonen et al., 2002). The head was placed in the 
Frankfort plane with hands freely at the sides. The scapular and buttocks were placed 
close to the vertical sliding metallic bar to ensure accurate readings. The sliding 
metallic bar gently rested on the subject’s head. If the participant was taller than the 
investigator, then investigator stood on a platform to enable an accurate reading.  
4.7.3 Waist circumference. 
A non-elastic tape that had been inspected for calibrations and stretch was used to 
measure the waist circumference (Waist C) (cm). Subjects were asked to stand in an 
erect position with hands placed on their sides and with their feet and abdominal 
muscles relaxed. Measurements were taken with the investigator in front of the 
participant by placing the measuring tape around the natural waist (narrowest part of 
the torso as seen from the anterior view). For obese participants, the narrowest 
circumference between the ribs and the iliac crest was measured  (Tolonen et al., 
2002). 
4.7.4 Hip circumference. 
The hip circumference (Hip C) (cm) was measured at the maximal circumference over 
the buttocks. A non-elastic tape was also used for this measurement. The investigator 
would place the tape around the buttocks on the widest area over the horizontal 23 
plane without pressing tightly against the skin, and then take the measurement 
(Tolonen et al., 2002). 
4.7.5 Waist to hip ratio 
This was calculated as the waist circumference per hip circumference. 





4.8 Laboratory measurements. 
4.8.1 Sample collection: whole blood and serum. 
4.8.1.1 Whole blood samples. 
Whole blood samples were collected into EDTA blood tubes and samples were frozen 
at -20°C. For the current study, DNA was extracted from these samples and used to 
determine VDR gene polymorphisms. 
4.8.1.2 Serum samples. 
Fasting blood samples were collected from participants in BD Vacutainer (SST) tubes 
(serum), for vitamin D level estimation. Serum samples were centrifuged, and aliquots 
were frozen at -80°C, which were then used for vitamin D binding protein 
determination. These results were used to investigate a possible association between 
Vitamin D, Vitamin D binding proteins and VDR polymorphisms in diabetic and non-
diabetic subjects. 
4.8.2 Biochemical data collection. 
Biochemical measurements: Plasma glucose concentrations were measured using 
the hexokinase method (Cobas 6000, Roche Diagnostics; Mannheim, Germany), 
HbA1c was measured using high performance liquid chromatography (HPLC)(Biorad 
Variant Turbo), Insulin was measured using a Paramagnetic particle assay 
(Chemiluminescence),  Fructosamine was measured using a Colorimetric test nitro-
blue-tetrazolium  (Roche Cobas c311), LDL-chol (mmol/L) was measured using  an 
Enzymatic Selective Protection –Endpoint assay (Beckman AU), HDL-C (mmol/L)  
using an Enzymatic Immunoinhibition-Endpoint assay (Beckman AU) and the 
triglycerides were estimated using a glycerol phosphate oxidase in the presence of 
peroxidase (GPO-POD) Endpoint assay (Beckman AU). 
4.8.3 Definitions and calculations.  
4.8.3.1 Body Mass Index (BMI). 
Body mass index is widely used as an estimate for prevalence of obesity. Hence, 
Obesity was classified using the BMI values recommended by (World Health 
Organization, 2016). The formula used is body weight (kg) / (height (m))2, was 
classified as follows: 
• Underweight: < 18.50 kg/m2 





• Normal range: 18.50 to 24.99 kg/m2 
• Overweight: ≥ 25.00 to 29.99 kg/m2 
• Obese: ≥ 30.00 kg/m2 
4.8.3.2 Homeostatic model assessment of insulin resistance (HOMA-IR). 
HOMA-IR was calculated from fasting insulin and fasting glucose. HOMA-IR had the 
formula (fasting insulin [mIU/L]) x (fasting glucose[mmol/L])/22.5 (Zhang et al., 2016). 
4.8.3.3 Vitamin D status. 
Vitamin D deficiency was diagnosed as 25(OH)D levels <20 ng/mL, vitamin D 
insufficiency was defined as 25(OH)D levels between 20 ng/mL and 29.9 ng/mL, and 
vitamin sufficiency as 25(OH)D ≥30 ng/mL according to the Endocrine Clinical Society 
Practice Guidelines for vitamin D deficiency (Holick et al., 2011). 
4.8.4 Determination of serum vitamin D levels. 
Currently serum 25(OH)D concentrations is the best representative measure of 
vitamin D status, as serum 1.25-(OH)D3 is highly regulated by parathyroid hormone 
(PTH), calcium and phosphorous levels in the circulation and are thus kept within 
normal ranges (Holick et al., 2008). Therefore, 1.25-(OH)D3 is not a reliable measure 
for vitamin D status. In the present study, Vitamin D levels were measured at PathCare 
Laboratories (Cape Town, Western Cape, South Africa), using the paramagnetic 
particle chemiluminescence test on a Beckman DXI. 
Access 25(OH) vitamin D total assay is a paramagnetic-particle, chemiluminescence 
Immunoassay used for the quantification of total 25(OH)D concentrations in serum and 
plasma using Unicell DXI Immunoassay systems. 
4.8.5 Determination of serum vitamin D binding proteins (VDBP). 
The concentrations of Vitamin D binding protein (VDBP) in serum samples was 
measured using the Human Vitamin D BP Quantikine ELISA kit (DVDBP0; R&D 
Systems, Minneapolis, MN, USA) (Freeman et al., 2014). This kit is designed 
specifically for measurement of DBP in serum, plasma, human milk, saliva and urine. 
Principle of the assay. 
4.8.5.1 Principle of the Human Vitamin D BP Quantikine ELISA. 
This kit uses a polyclonal competitive ELISA method. The microwell plates of the kit 
are pre-coated with antibody specific to DBP. Standards or samples are added along 





with biotinylated GC Globulin to microwell plate and will be incubated for the first time. 
After incubation period, unbound contents are washed away with wash buffer. 
Streptavidin-Peroxide Conjugate is added, and unbound conjugates are washed away 
with wash buffer for the second time. TMB substrate is then added to visualize 
Streptavidin-Peroxidase enzymatic reaction. Streptavidin-Peroxidase catalyse TMB to 
produce a blue colour product. Addition of acid solution terminate enzyme-substrate 
reaction thus resulting in yellow colour. Absorbance of standards or samples are 
measured by ELISA plate reader with a wavelength set at 450 nm. The density of 
yellow coloration is inversely proportional to the amount of GC globulin captured in the 
plate.  
Intra-Assay CV = 2.2-21% 
Inter-Assay CV% = 6.5-2.1% 
Reference range =168-367 µg/mL. 
Standard deviation (SD) = 51.3 µg/mL. 
4.8.5.2 Assay method performance. 
All reagents, standards and samples were prepared according to manufacturer’s 
instructions. The assay uses 96-well plate pre-coated with Human Vitamin D BP. 
Firstly, 50 µl of Assay Diluent RD1-38 was added to each well, with subsequent 
addition of 50 𝜇𝜇l of standard (in duplicate) and sample (not in duplicate) per well. The 
plate was covered with adhesive strip and incubated for 2 hours at room temperature 
on a microplate shaker set at 500±50 rpm. After incubation, fluid was aspirated from 
each well and washed three times (3x) by filling each well with 400 𝜇𝜇l wash buffer 
using auto washer. In the second incubation, human vitamin D conjugate (200 𝜇𝜇l) is 
added to each well. The plate was then covered with adhesive strip and incubated for 
1 hour at room temperature on the microplate shaker. After incubation a wash step 
was carried again 3 times. Thirdly, 200 𝜇𝜇l of substrate solution was added to each well 
and incubated for 30 minutes at room temperature on the benchtop. After 30 minutes 
of incubation, stop solution (50 𝜇𝜇l) was added to each well, followed by gently taping 
top of the plate until a colour change appears. Microplate reader set at 450 nm was 
used to determine the optical density of each well. The density of the colour was 
proportional to the amount of Vitamin D present in the serum sample. 





4.8.6 Determination of the vitamin D receptor polymorphisms. 
4.8.6.1 DNA extraction. 
Genomic DNA was extracted from the whole blood using a salting-out extraction 
method (Maurya et al., 2013). 24 tubes were labelled with relevant sample ID. 2 ml of 
thawed blood were transferred into each tube. Working on ice, 10 ml of lysis buffer 
were added to each tube. Vortex step was carried out and all tubes were centrifuged 
at 1500 rpm 4°C for 10 minutes. Supernatant were discarded, and nuclei pellets were 
retained and resuspended in 10 ml PBS buffer. After resuspension in 10 ml PBS, 
vortex step was carried out and all tubes were centrifuged at 1500 rpm at 4°C for 10 
mins. Supernatant were discarded, and nuclei pellets were dissolved in 3 ml nucleic 
lysis buffer, 300𝜇𝜇𝜇𝜇 10% SDS and 30 𝜇𝜇𝜇𝜇 proteinase K (10mg/ml).  vortex step was 
carried out and all tubes were incubated overnight at 55°C (water bath full). 
1 ml of saturated 6M NaCl was added to each incubated tube. Vortex step was carried 
out not too vigorously and the tubes were centrifuged at 2500rpm at 4°C for 30 mins.  
Supernatants were then transferred into new tubes and pellets were discarded. Two 
volumes of cold absolute ethanol were added into each tube, and tubes were inverted 
several times until DNA precipitate appear. DNA was precipitated by adding two 
volumes of ice cold 100% ethanol (ETOH) and then tube was tilted until DNA 
precipitates. Precipitated DNA was transferred into Eppendorf tube and resuspended 
in 1ml of ice cold 70% ethanol. Vortex step was carried out and tubes were centrifuged 
at maximum speed for 30 minutes. Supernatant were discarded, and pellet retained. 
Pellets were dissolved in 100-200 µL distilled water. Eppendorf tubes were put on 
turning apparatus for overnight and DNA concentration was read on Nanodrop 
Analyzer spectrophotometer (Thermo Scientific™ Nano-Drop™ One Microvolume 
UV-Vis Spectrophotometers). The 260/280 ratio nm was used to assess purity of the 
DNA and values between 1.8-2.2 were considered for high quality. 
4.8.6.2 Vitamin D receptor polymorphisms genotyping. 
The VDR gene polymorphisms were selected to perform genotyping according to the 
published literature searched on science direct, NCBI, Ensembl.org genome browser 
92 and their association with disease susceptibility. The representative SNPs of the 
VDR selected for genotyping include Fok1 (rs2228570), Apa1 (rs7975232) and Taq1 
(rs731236) refer to the table below. Table 4.1 shows the list of SNPs selected for 





genotyping based on the literature search on science direct, PubMed, Ensembl.org 
genome browser 92 and NCBI web, as well as their respective sources. The genomic 
coordinates for each SNP are given as well as the allele frequencies of underlined 
alleles of the SNP for African populations and Caucasians of European descendance 
in the HapMap.

















(Malik et al., 2017) 
(Abdeltif et al., 2014) 
48272895 C/T/G/A 58.8 80.8 
Apa1 
(rs7975232) 
(Cyganek et al., 
2006) 
 
48238837 G/T 42.9 37.2 
Taq1 
(rs731236) 
(Dilmec et al., 2010) 48238757 T/C 56.2 71.2 
All SNPs genotyping were performed using the TaqMan SNP Genotyping Assays 
(Applied Biosystems, USA) (Riedemann et al., 2008) on the QuantStudio 7 Flex 
system and confirmed by direct sequencing. Primers used for genotyping of the single 
nucleotide of the VDR are displayed on table 4.2. These primers are pre-designed and 
found within the TaqMan SNP genotyping Assay.  
Table 4.2: Primers used for genotyping from Thermo fisher scientific company. 



















4.8.6.3 TaqMan SNP Genotyping Assay principle. 
This assay uses 5’ nuclease to amplify and detect specific SNP allele in a purified 
genomic DNA sample. The assay consists of sequence-specific primers and two 
probes each with specific reporter (VIC/FAM) dye attached at the 5’ end and a minor 
groove binding (MGB) with quencher attached at the 3’ end. Each TaqMan probe binds 
to complementary sequence on the DNA template between forward and reverse 
primer sites. Proximity of the reporter to the quencher results in quenching of the 





reporter fluorescence by foster resonance energy transfer (FRET) phenomenon. 
AmpliTaq Gold DNA polymerase extends primers, and further cleaves the probes 
hybridized to the target sequence on the DNA template. 
Cleavage of the probes separate reporter dye from the quencher, thus resulting in high 
fluorescence of the reporter. Fluorescence signal generated during PCR amplification 
when probes hybridize to complementary sequences indicates presence of a SNP 
allele in the DNA sample. Substantial increase in VIC dye only indicates detection of 
homozygote Allele 1, increase in FAM dye indicates homozygote Allele 2 and if 
fluorescence signals both VIC and FAM dyes then it indicates Allele 1-Allele 2 
heterozygosity. 
4.8.6.4 Method performance for SNP genotyping. 
A cocktail mix for one hundred and five (105) samples was first prepared in an 
Eppendorf tube prior to adding into the MicroAmp fast optical 96-well reaction plate. 
The cocktail was made from 5 𝜇𝜇l TaqMan SNP genotyping Mix, 0.25 𝜇𝜇l TaqMan SNP 
genotyping Assays and 3.75 𝜇𝜇l Nuclease free water. Nine microlitres (9 𝜇𝜇l) of cocktail 
mix was added into each well of the plate and subsequently 2 𝜇𝜇l genomic DNA was 
added into the first 93 wells of the plate with respect to sample ID. Two microlitres 
(2 𝜇𝜇l) of nuclease free water were added into the last three wells, thus serving as no 
template controls (NTC) or negative controls. Each well had total reaction volume of 
11 𝜇𝜇l (9 𝜇𝜇l cocktail + 2 𝜇𝜇l genomic DNA/Nuclease free water). The plate was then 
sealed with MicroAmp optical adhesive film and centrifuged for five seconds (5s) at 
maximum speed. Thereafter, the plate was loaded in the Quantstudio 7 flexi (Quantum 
7, Life Technologies, South Africa) real time PCR systems and PCR was initiated at 
95°C for 10 min, followed by 40 cycles of 92°C for 15 sec and 60°C for 60 secs. 
                       A                                                                   B          
           





Figure 4.1 Overview of the 96 well plate orientation (A) and real time PCR optical 
reaction plate (B) 
  
Figure 4.2 Schematic representation of the TaqMan SNP Genotyping assays 
chemistry overview. 
4.9 Statistical analysis  
Data were analysed using a software program, Statistica 13.3 (StatSoft, Southern 
Africa). Comparison analysis between groups were expressed as mean and standard 
deviation. Correlation studies (R- and P-values) were used to assess the relationship 
between variables tested. The Pearson Chi-square test was used to determine 
association between SNPs genotypes and/or allele frequencies and vitamin D 
deficiency, obesity and hyper-glycaemia categories. A multiple linear regression 
model (b* and P-value) was used to establish possible association between vitamin D 
(dependent variable) and other test results. Hardy-Weinberg Equilibrium was tested 
using the chi-square (x2) method to compare the observed and expected genotypes 
and alleles frequency between T2DM and non-diabetic patients. For all analysis 
statistical significance was set at a probability (p) of < 0.05.





Chapter 5 Results 
5.1 Characteristics of participants categorized according to gender. 
Anthropometric and biochemical characteristics are displayed in table 5.1. The 
average age of participants was 49.6±15.2 years. Females were significantly older 
than males (50.2±14.9 (20-90 years) vs 47.8±16.0 range (20-86 years), P=0.0054 
respectively). Anthropometric measurements, BMI (kg/m2), Waist C (cm) and Hip C 
(cm) were all significantly higher in females than in males (All, P<0.0001). Vitamin D 
(25(OH)D levels were significantly higher in males compared to females (23.6±7.9 vs 
21.5±7.5, P=0.0006) respectively, whereas serum VDBP levels were significantly 
higher in females compared to males (315.9±76.1 vs 299.1±71.2, P=0.0001) 
respectively. Females compared to males, they had significantly higher FBG (mmol/L), 
2 hr BG (mmol/L), HbA1c) (%), FBI (mIU/L), 2 hr BI (mIU/L), HDL-C (mmol/L), LDL-C 
(mmol/L), cholesterol (mmol/L) and Parathormone (pmol/L) (All P≤0.0110). In contrast, 
males compared to females, they had significantly higher Creatinine-S (umol/L), 
Creatinine-U (mmol/L), Albumin-S (g/L), Sodium-U (mmol/L), Cotinine (ng/mL) and 
Gamma GT-S (IU/L) were significantly higher in males than in females (All, P≤0.0321). 
 





Table 5.1: Participants characteristics according to gender.  
 Total, N= 1603 Males, N= 387 Females, N= 1216  
 Mean ± SD P-value 
Age (years) 49.6±15.2 47.8±16.0 50.2±14.9 0.0054 
Anthropometric measurements     
BMI (kg/m2) 29.4±8.1 24.7±6.2 30.9±8.0 <0.0001 
Waist C (cm) 93.0±17.0 86.4±16.7 95.2±16.5 <0.0001 
Hip C (cm) 104.9±16.2 94.7±12.3 108.2±15.9 <0.0001 
WHR 0.89±0.09 0.91±0.09 0.88±0.08 <0.0001 
Biochemical measurements     
Vitamin D (25(OH)D ng/mL) 22.0±7.6 23.6±7.9 21.5±7.5 0.0006 
Serum VDBP (µg/mL) 311.8±75.2 299.1±71.2 315.9±76.1 0.0001 
FBG (mmol/L) 5.84±2.99 5.43±2.24 5.97±3.19 0.0023 
2 hr BG (mmol/L) 6.68±3.09 5.81±3.06 6.97±3.05 <0.0001 
HbA1c) (%) 6.25±1.64 5.97±1.30 6.34±1.73 0.0001 
FBI (mIU/L) 9.30±9.34 7.58±9.48 9.85±9.22 <0.0001 
2 hr BI (mIU/L) 56.0±53.3 35.0±39.4 62.9±55.5 <0.0001 
Glucose/Insulin ratio 1.01±0.91 1.30±1.04 0.91±0.84 <0.0001 
HOMA-IR 2.56±3.47 2.05±3.95 2.73±3.29 0.0009 
Triglycerides (mmol/L) 1.49±1.32 1.52±1.52 1.49±1.25 0.6762 
HDL-C (mmol/L) 1.32±0.36 1.26±0.37 1.34±0.36 0.0002 
LDL-C (mmol/L) 3.25±1.04 2.96±1.00 3.34±1.04 <0.0001 
Cholesterol (mmol/L) 5.19±1.19 4.84±1.16 5.30±1.17 <0.0001 
Cholesterol/HDL ratio 4.13±1.18 4.04±1.26 4.16±1.16 0.0967 
Gamma GT-S (IU/L) 46.8±72.4 53.7±97.3 44.6±62.3 0.0321 
Creatinine-S (umol/L) 64.7±39.1 77.1±33.3 60.7±40 To conser.0 <0.0001 
Creatinine-U (mmol/L) 13.5±8.3 15.5±8.7 12.9±8.1 <0.0001 
ALT (SGPT) (IU/L) 23.6±38.0 26.1±20.7 22.8±42.0 0.1430 
AST (SGOT) (IU/L) 26.8±32.3 29.0±16.9 26.1±35.8 0.1229 
MDRD (mL/min/1.73m2) 84.4±12.2 84.5±12.7 84.3±12.0 0.7975 
Parathormone (pmol/L) 5.46±3.42 4.92±3.67 5.60±3.34 0.0110 
Albumin-S (g/L) 42.9±3.3 43.6±3.8 42.7±3.2 0.0003 
Calcium-S (mmol/L) 2.45±3.14 2.35± 2.48±3.52 0.5906 
Phosphate-S (mmol/L) 1.59±15.69 1.04±0.17 1.73±17.64 0.5743 
Sodium-U (mmol/L)  108.6±54.0 121.3±57.0 105.3±52.8 0.0002 
CRP (mg/L) 8.6±15.8 8.5±17.6 8.6±15.1 0.9760 
Cotinine (ng/mL) 138.6±159.9 157.7±153.1 132.6±161.6 0.0078 
Smoking, Yes %(N) 48.3% (758/1568) 59.0% (222/376) 45.0% (536/1192) <0.0001* 
     
*Pearson Chi-square    
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5.2 Stratification of participant characteristics according to gender and 
glycaemic status (Table 5.2). 
Anthropometric measurements including the BMI (kg/m2), Waist C (cm) and Hip C 
(cm) were significantly higher in hyper-glycaemic group than in normo-glycaemic 
males and females (All, P<0.0001). Overall higher BMI (kg/m2) values were seen in 
females, which progressively increased in normo-glycaemic (29.7±8.0) to pre-DM 
(33.2±8.0) and then screen-detected (33.4±7.) and known DM (32.2±7.0) subjects. 
Vitamin D (25(OH)D ng/mL) was in general significantly decreased in both genders in 
the hyper-glycaemic sub-groups. In males, Vitamin D (25(OH)D ng/mL) levels were 
24.2±8.2 ng/mL in normo-glycaemic and 17.0±6.1 ng/mL in screen-detected DM 
subjects (P=0.0214) and in females 22.4±7.9 ng/mL in normo-glycaemic and 21.1±6.0 
ng/mL in screen-detected DM subjects (P=0.0007). In contrast, there were no 
significant differences in Serum VDBP (µg/mL) between the glycaemic sub-groups in 
either male (P=0.5614) or females (P= 0.4813). The glycaemic parameters as 
expected were significantly increased in the hyper-glycaemic sub-groups in both 
genders, including FBG (mmol/L), 2 hr BG (mmol/L), HbA1c (%), FBI (mIU/L), 2 hr BI 
(mIU/L) and HOMA-IR (All, both males and females P<0.0001).  
In general, the lipids, including the triglycerides (mmol/L), LDL-C (mmol/L) and 
Cholesterol (mmol/L) were also significantly increased in both genders in the hyper-
glycaemic sub-groups (All, males P≤0.0300, females P<0.0001), while HDL-C 
(mmol/L) was significantly decreased in both males and females in the hyper-
glycaemic sub-groups (All, P≤0.0308). Gamma GT-S (IU/L) was significantly 
increased in both genders in the hyperglycaemic sub-groups (All, P≤0.0144). 
Creatinine-S (umol/L) was significantly increased in male subjects with hyper-
glycaemia (P =0.0003) and creatinine-U (mmol/L) in female subjects with hyper-
glycaemia (P=0.0049). The MDRD (mL/min/1.73m2) and Sodium-U (mmol/L) were 
significantly decreased in both genders in subjects with Hyper-glycaemia (All, 
P≤0.0083). The CRP (mg/L) was near significantly increased in males (P=0.0742) and 
significantly increased in females (P=0.0031) in the hyper-glycaemic sub-groups. 
Cotinine (ng/mL) was significantly decreased in both genders in the hyperglycaemic 
sub-groups (All, P≤0.0024)





Table 5.2: Stratification of participant characteristics according to gender and glycaemic status. 





















DM, N=171  
 Mean ± SD P-value  Mean ± SD P-value 
Age (years) 43.7±15.1 56.5±13.7 59.6±11.8 60.2±12.5 <0.0001  46.3±15.1 55.3±13.2 58.2±10.7 57.8±11.3 <0.0001 
Anthropometric measurements           
BMI (kg/m2) 23.7±5.9 25.1±6.0 28.7±6.7 28.6±5.9 <0.0001  29.7±8.0 33.2±8.0 33.4±7.5 32.2±7.0 <0.0001 
Waist C (cm) 82.5±14.4 90.1±15.2 100.9±17.4 101.1±19.0 <0.0001  91.6±16.7 100.6±14.8 102.7±13.8 100.5±14.7 <0.0001 
Hip C (cm) 92.9±12.1 96.3±12.9 102.4±12.8 100.9±9.7 <0.0001  106.2±16.0 112.3±15.7 112.3±15.0 110.0±14.7 <0.0001 
WHR 0.89±0.08 0.93±0.07 0.98±0.08 1.00±0.13 <0.0001  0.86±0.08 0.90±0.07 0.92±0.07 0.92±0.07 <0.0001 
Biochemical measurements           
Vitamin D (25(OH)D ng/mL) 24.2±8.2 22.4±6.7 17.0±6.1 24.4±7.1 0.0214  22.4±7.9 20.5±7.4 21.1±6.0 19.6±5.5 0.0007 
Serum VDBP (µg/mL) 302.3±73.7 290.7±58.7 291.7±63.4 290.0±68.6 0.5614  314.7±76.5 319.7±74.3 307.3±74.1 320.7±77.2 0.4813 
FBG (mmol/L) 4.66±0.59 5.32±0.69 9.34±4.38 8.82±3.49 <0.0001  4.77±0.49 5.34±0.64 8.23±4.21 10.94±5.34 <0.0001 
2 hr BG (mmol/L) 4.84±1.32 8.55±1.41 15.14±5.69 Not done <0.0001  5.67±1.20 8.83±1.10 14.36±4.99 Not done <0.0001 
HbA1c (%) 5.53±0.44 5.71±0.50 7.34±1.62 8.27±2.11 <0.0001  5.63±0.47 6.02±0.51 7.65±2.34 9.20±2.43 <0.0001 
FBI (mIU/L) 6.2±6.5 9.2±12.2 17.1±23.5 11.2±10.7 <0.0001  8.2±6.4 12.1±11.6 12.3±8.1 13.2±14.1 <0.0001 
2 hr BI (mIU/L) 29.7±34.3 66.6±56.7 44.6±29.8 Not done <0.0001  52.2±47.2 100.5±69.4 67.4±45.4 Not done <0.0001 
Glucose/Insulin ratio 1.28±0.89 1.35±1.06 0.93±0.61 1.53±1.72 0.2217  0.83±0.49 0.70±0.53 1.02±1.17 1.51±1.60 <0.0001 
HOMA-IR 1.32±1.60 2.33±3.40 8.21±14.39 3.91±3.23 <0.0001  1.77±1.45 2.96±3.20 4.47±3.95 5.85±5.73 <0.0001 
Triglycerides (mmol/L) 1.35±1.10 1.28±0.70 3.72±4.07 1.92±1.87 <0.0001  1.29±0.78 1.77±2.33 1.68±0.85 1.92±1.03 <0.0001 
HDL-C (mmol/L) 1.28±0.39 1.30±0.35 1.13±0.23 1.14±0.23 0.0308  1.36±0.36 1.33±0.35 1.29±0.40 1.28±0.33 0.0211 
LDL-C (mmol/L) 2.91±1.00 3.13±0.88 3.61±1.15 2.90±0.94 0.0300  3.21±1.03 3.55±1.00 3.57±0.94 3.55±1.06 <0.0001 
Cholesterol (mmol/L) 4.79±1.17 5.03±0.92 5.71±1.47 4.70±1.06 0.0076  5.16±1.16 5.53±1.15 5.54±1.09 5.53±1.23 <0.0001 
Cholesterol/HDL ratio 3.94±1.22 4.09±1.27 5.08±1.45 4.23±1.26 0.0031  3.99±1.15 4.37±1.10 4.50±1.15 4.50±1.10 <0.0001 
Gamma GT-S (IU/L) 47.6±73.2 43.3±33.0 109.1±158.3 79.7±186.5 0.0144  41.6±61.3 45.5±46.0 66.8±115.2 46.3±43.1 0.0059 
Creatinine-S (umol/L) 72.8±15.5 85.8±53.3 85.4±57.9 92.6±61.0 0.0003  60.2±47.2 59.0±14.0 60.9±21.1 64.4±32.6 0.5872 
Creatinine-U (mmol/L) 14.9±8.4 18.0±9.9 15.6±10.0 16.0±8.7 0.4167  13.0±7.8 13.0±8.9 16.0±9.9 11.1±6.7 0.0049 
ALT (SGPT) (IU/L) 26.0±21.3 22.6±15.1 29.9±20.5 28.2±21.4 0.5247  21.9±48.8 22.6±16.0 34.8±54.0 21.5±15.1 0.0624 
AST (SGOT) (IU/L) 29.2±15.1 27.6±11.1 28.2±16.1 29.4±28.0 0.9490  26.1±42.3 26.3±22.1 32.5±27.4 22.7±14.1 0.2470 
MDRD (mL/min/1.73m2) 86.4±9.2 80.2±17.7 80.9±18.6 78.2±19.4 <0.0001  85.4±10.8 84.1±10.7 82.5±14.6 80.9±16.1 0.0001 
Parathormone (pmol/L) 4.40±2.00 5.76±5.37 6.87±8.51 5.67±4.43 0.0375  5.58±3.56 5.41±2.40 5.91±2.33 5.82±3.85 0.6856 
Albumin-S (g/L) 43.7±4.1 43.6±3.3 42.5±3.9 43.8±2.7 0.7950  42.8±3.3 42.9±2.7 42.3±2.5 42.1±3.3 0.1341 
Calcium-S (mmol/L) 2.35±0.11 2.35±0.11 2.33±0.14 2.34±0.10 0.9553  2.35±0.11 3.02±8.05 2.35±0.09 2.38±0.14 0.2282 
Phosphate-S (mmol/L) 1.05±0.16 1.01±0.16 1.05±0.26 1.03±0.18 0.6230  1.10±0.17 4.43±40.52 1.06±0.15 1.11±0.18 0.2331 
Sodium-U (mmol/L)  127.0±58.7 128.3±57.2 72.0±34.8 108.4±45.7 0.0083  112.4±54.6 99.7±51.9 93.3±47.4 88.3±42.2 <0.0001 
CRP (mg/L) 7.6±16.5 10.6±20.7 18.7±29.1 8.6±15.6 0.0742  7.3±13.0 10.0±13.4 11.3±14.0 11.0±23.6 0.0031 
Cotinine (ng/mL) 171.8±152.3 164.3±163.2 115.1±138.2 84.3±133.8 0.0024  145.5±162.6 138.2±166.3 74.6±131.3 96.7±153.9 <0.0001 
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Figure 5.1 Summary of the prevalence of optimal Vitamin D (25(OH)D ng/mL) levels 
in the current population study, categorized according to gender. 
 
 
Figure 5.1: The prevalence of optimal vitamin D levels was very low in the current study 
population, in males, only 18.9% (38/201) had optimal vitamin D levels, while 45.3% 
(91/201) had insufficient and 35.8% (72/201) had deficient vitamin D levels. In females, 
the prevalence of optimal vitamin D levels was also very low, respectively 11.5% 
(88/767), 41.9% (321/767) and 46.7% (358/767) (Overall, P=0.0033). For the total 
group, the prevalence was 13.0% (126/968), 42.6% (412/968) and 44.4% (430/968) 
respectively (data shown elsewhere). Vitamin D (25 OH)D) groupings have been 
classified as follows: deficient levels are <20 ng/mL, insufficient levels are between 20 
and 29 ng/mL and optimal levels are ≥30 to 100 ng/mL (Lakshmi et al., 2015). None 
of the subjects exceeded the maximum level.
 The prevalence of optimal levels of Vitamin D (25-(OH)D ng/mL) in 



























Figure 5.2 Summary of the prevalence of optimal Vitamin D (25(OH)D ng/mL) based 
on BMI, categorized according to gender. 
 
Figure 5.2: The prevalence of optimal levels of Vitamin D (25(OH)D ng/mL) was very 
low for both genders in both normal weight and overweight/obese subjects. In males, 
the prevalence was 19.2% (20/104) in normal weight and 18.8% in overweight/obese 
subjects (P=0.9310 {Chi-square}). In females, this difference was statistically 
significant with the prevalence of 21.5% (32/149) and 9.0% (55/614) ((P<0.0001 {Chi-
square}) respectively. [The prevalence of obesity has been reported to be high in the 
community from which the current study population has been recruited (Matsha et al., 
2013) and a similarly high prevalence has been shown in the current study population 
and higher in females than in males (P<0.0001). In the total group 32.8% (524/1596) 
were of normal weight, 24.1% (384/1596) were overweight and 43.1% (688/1596) 
were obese. In males, the prevalence was respectively 60.3% (232/385), 24.4% 
(94/385) and 15.3% (59/385), while in females it was respectively 24.1% (292/1211), 
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Figure 5.3 Summary of the prevalence of optimal Vitamin D (25(OH)D ng/mL) levels 
in normo-glycaemic and hyper-glycaemic subjects, categorized by gender. 
 
Figure 5.3: The prevalence of optimal levels of Vitamin D (25(OH)D ng/mL) was very 
low for both genders in both normo-glycaemic and hyper-glycaemic subjects. In males, 
the prevalence of optimal levels of Vitamin D (25(OH)D ng/mL) was 18.9% (25/132) in 
normo-glycaemic and 18.8% (13/69) in hyper-glycaemic subjects, with no significant 
difference between the glycaemic groups (P=0.9865 {Chi-square}), in females, this 
difference was statistically significant with the prevalence of 15.1% (69/457) in normo-
glycaemic and 6.1% (19/310) in hyper-glycaemic subjects ((P<0.0003 {Chi-square}). 
[Similar to the prevalence of obesity, the prevalence of hyperglycaemia has been 
reported to be high in the South African mixed ancestry population (Erasmus et al., 
2012).In the current study population, the prevalence of hyperglycaemia was similarly 
high and also significantly higher in females  (P=0.0010). In the total group, 64.8% of 
subjects (1039/1603) were normo-glycaemic, 15.3% (246/1603) were pre-DM, 6.2% 
(100/1603) were screen-detected DM and 13.6% (218/1603) were Known DM. In 
males, the prevalence was respectively, 72.9% (282/387), 10.6% (41/387), 4.4% 
(17/387) and 12.1% (47/387) and in females respectively 62.3% (757/1216), 16.9% 
(205/1216), 6.8% (83/1216) and 14.1% (171/1216).
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5.3 Correlation of Vitamin D (25(OH)D ng/mL) levels with anthropometric 
and biochemical measurements according to gender. 
Vitamin D (25-(OH)D ng/mL) showed highly significant correlations in females 
compared to males with both anthropometric and biochemical measurements. Vitamin 
D (25(OH)D ng/mL) correlated significantly inversely with the BMI (kg/m2), the Waist 
C (cm) and the Hip C (cm) in females, with the strongest inverse correlation with the 
BMI (kg/m2) (R=-0.1839, P<0.0001). Vitamin D (25(OH)D ng/mL) correlated 
significantly positively with serum VDBP (µg/mL) in females (R=0.0969, P=0.0073), 
but not in males (R=0.0767, P=0.2802). Vitamin D (25(OH)D ng/mL) correlated 
significantly inversely with the glycaemic measurements, including FBG (mmol/L), 2 
hr BG (mmol/L), HbA1c) (%), FBI (mIU/L), 2 hr BI (mIU/L) and HOMA-IR, with the 
strongest significant inverse correlation with HOMA-IR (R=-0.1907, P<0.0001). In 
males, Vitamin D (25(OH)D ng/mL) showed a significantly inverse correlation with Post 
2 hr BG (mmol/L) (R=-0.2646, P=0.0006).  
Similarly, glycaemic profile and Vitamin D (25(OH)D ng/mL) showed highly significant 
correlations with the lipids in females, but very few in males. In females, Vitamin D 
(25(OH)D ng/mL) showed significant inverse correlations with  triglycerides (mmol/L), 
LDL-C (mmol/L), Cholesterol (mmol/L), Creatinine-U (mmol/L) and Parathormone 
(pmol/L) (All, P≤0.0211) and significant positive correlations with HDL-C (mmol/L), 
Albumin-S and Calcium-S (mmol/L) (P≤0.0008). In males, Vitamin D (25(OH)D ng/mL) 
showed near-significant weak inverse correlations with the triglycerides (mmol/L), 
LDL-C (mmol/L) and Cholesterol (mmol/L) (All, P>0.05<0.10) and a significant positive 
correlation with AST (SGOT) (IU/L) (R=0.1526, P=0.0310). Vitamin D (25(OH) (ng/mL) 
showed significant inverse correlations with the CRP (mg/L) in males and females, 
respectively (R= -0.1441, P=0.0413 and R= -0.1049, P=0.0037).





Table 5.3: The correlation of Vitamin D (25(OH)D ng/mL) levels categorized by gender. 
 Total, N=968 Males, N=201 Females, N=767 
 R P-value R P-value R P-value 
Age (years) 0.0120 0.7092 -0.0230 0.7458 0.0188 0.6032 
Anthropometric measurements       
BMI (kg/m2) -0.2036 <0.0001 -0.1111 0.1175 -0.1839 <0.0001 
Waist C (cm) -0.1849 <0.0001 -0.1052 0.1383 -0.1788 <0.0001 
Hip C (cm) -0.1505 <0.0001 -0.0589 0.4075 -0.1237 0.0006 
WHR -0.1204 0.0002 -0.1190 0.0932 -0.1457 0.0001 
Biochemical measurements       
serum VDBP (µg/mL) 0.0808 0.0120 0.0767 0.2802 0.0969 0.0073 
FBG (mmol/L) -0.1503 <0.0001 -0.1270 0.0731 -0.1494 <0.0001 
2 hr BG (mmol/L) -0.1790 <0.0001 -0.2646 0.0006 -0.1407 0.0003 
HbA1c) (%) -0.1639 <0.0001 -0.0924 0.1918 -0.1737 <0.0001 
FBI (mIU/L) -0.1512 <0.0001 -0.0270 0.7048 -0.1547 <0.0001 
2 hr BI (mIU/L) -0.1274 0.0003 -0.1318 0.0896 -0.1047 0.0081 
Glucose/Insulin ratio 0.0871 0.0073 -0.0007 0.9925 0.0811 0.0258 
HOMA-IR -0.1822 <0.0001 -0.0619 0.3860 -0.1907 <0.0001 
Triglycerides (mmol/L) -0.1595 <0.0001 -0.1345 0.0570 -0.1630 <0.0001 
HDL-C (mmol/L) 0.0800 0.0129 0.0039 0.9562 0.1248 0.0005 
LDL-C (mmol/L) -0.1695 <0.0001 -0.1385 0.0517 -0.1619 <0.0001 
Cholesterol (mmol/L) -0.1526 <0.0001 -0.1339 0.0581 -0.1385 0.0001 
Cholesterol/HDL ratio -0.2088 <0.0001 -0.1387 0.0507 -0.2303 <0.0001 
Gamma GT-S (IU/L) 0.0001 0.9980 -0.0410 0.5630 0.0019 0.9577 
Creatinine-S (umol/L) 0.0956 0.0029 0.1222 0.0841 0.0399 0.2713 
Creatinine-U (mmol/L) -0.0626 0.0530 -0.0274 0.7003 -0.0838 0.0211 
ALT (SGPT) (IU/L) 0.0181 0.5734 0.0620 0.3821 -0.0055 0.8797 
AST (SGOT) (IU/L) 0.0903 0.0050 0.1526 0.0310 0.0599 0.0976 
MDRD (mL/min/1.73m2) -0.0099 0.7594 -0.0988 0.1662 0.0084 0.8190 
Parathormone (pmol/L) -0.1696 <0.0001 -0.1236 0.0805 -0.1658 <0.0001 
Albumin-S (g/L) 0.1321 <0.0001 0.0576 0.4171 0.1310 0.0003 
Calcium-S (mmol/L) 0.1243 0.0001 0.1360 0.0543 0.1206 0.0008 
Phosphate-S (mmol/L) 0.0363 0.2607 -0.0208 0.7696 0.0708 0.0507 
Sodium-U (mmol/L)  0.0291 0.3698 -0.0302 0.6711 0.0326 0.3716 
CRP (mg/L) -0.1250 0.0001 -0.1441 0.0413 -0.1049 0.0037 
Cotinine (ng/mL) 0.0899 0.0052 0.1028 0.1463 0.0747 0.0389 
       
*Pearson Chi-square 
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5.4 Correlation of Vitamin D (25(OH)D ng/mL) levels with anthropometric 
and biochemical measurements categorized by gender and glycaemic 
status. 
Vitamin D (25-(OH)D ng/mL) showed in general significant correlations with both 
anthropometric and biochemical measurements in normo-glycaemic female subjects 
and which were of lower significance or absent in the hyper-glycaemic female sub-
groups as well as in males. Vitamin D (25(OH)D ng/mL) showed significant inverse 
correlations with the BMI (kg/m2), the Waist C (cm) and the Hip C (cm) in normo-
glycaemic female subjects (All, P≤0.001) and with the BMI (kg/m2) in screen-detected 
DM female subjects (P=0.020). Vitamin D (25(OH)D ng/mL) showed a near-significant 
positive correlation with serum VDBP (µg/mL) in normo-glycaemic (R=0.087, P=0.064) 
and a significant positive correlation in pre-DM (R=0.216, P=0.008) female subjects 
as well as a near-significant positive correlation in screen-detected DM male subjects 
(R=0.539, P=0.108). Vitamin D (25 OH)D ng/mL) showed in general significant inverse 
correlations with the glycaemic measures in normo-glycaemic female subjects, 
including  2 hr BG (mmol/L), HbA1c) (%), FBI (mIU/L),  2 hr BI (mIU/L) and HOMA-IR 
(All, P≤0.049) as well as significant inverse correlations with FBG (mmol/L) and 
HbA1c) (%) (All, P≤0.011) in screen-detected DM female subjects, but a significant 
positive correlation with 2 hr BI (mIU/L) (P=0.022) in screen-detected DM female 
subjects. 
In the males, Vitamin D (25(OH)D ng/mL) showed significant inverse correlations with 
2 hr BG (mmol/L) in normo-glycaemic males (P=0.012) and with FBI (mIU/L) in screen-
detected males (P=0.010). Vitamin D (25(OH)D ng/mL) showed primarily significant 
correlations with the lipid profile measurements in the normo-glycaemic, pre-DM and 
known DM female subjects, but not in the Screen-detected female subjects, these 
include inverse correlations with the Triglycerides (mmol/L) and LDL-Cl (mmol/L) and 
positive correlations with HDL-C (mmol/L) (All, P≤0.0490). In the males, in contrast, 
Vitamin D (25(OH)D ng/mL) correlated significantly inversely with HDL-C (mmol/L) in 
the pre-DM males (R=-0.390; P=0.044), but near-significantly positively in the screen-
detected males (R=0.537; P=0.109). Vitamin D (25(OH)D ng/mL) correlated 
significantly inversely with parathormone (pmol/L) in normo-glycaemic, pre-DM as well 
as in screen-detected DM (P≤0.047) female subjects.





Table 5.4: The correlation of Vitamin D (25(OH)D ng/mL) levels with anthropometric and biochemical measurements 
categorized by gender and glycaemic status. 
 Males, N387  Females, N1216 
 Normo- glycaemic, N132 Pre-DM, N27 
Screen 
Detected DM, N11 Known DM, N31  
Normo- 
glycaemic, N457 Pre-DM, N148 
Screen- 
detected DM, N53 Known DM, N109 















Age (years) -0.035 0.690 -0.198 0.321 0.082 0.811 0.459 0.009  0.012 0.803 0.141 0.088 0.165 0.239 0.159 0.098 
Anthropometric measurements                  
BMI (kg/m2) -0.126 0.152 0.162 0.421 -0.482 0.133 0.047 0.803  -0.185 <0.001 -0.120 0.147 -0.320 0.020 -0.028 0.774 
Waist C (cm) -0.116 0.186 0.101 0.615 -0.555 0.077 0.143 0.442  -0.186 <0.001 -0.074 0.368 -0.204 0.143 -0.036 0.711 
Hip C (cm) -0.068 0.442 0.213 0.287 -0.382 0.247 -0.037 0.843  -0.155 0.001 -0.005 0.950 -0.215 0.122 0.017 0.863 
WHR -0.120 0.172 -0.028 0.890 -0.597 0.053 0.164 0.377  -0.113 0.016 -0.111 0.177 0.119 0.395 -0.180 0.062 
Biochemical measurements                 
serum VDBP (µg/mL) 0.023 0.791 0.037 0.856 0.539 0.108 0.116 0.535  0.087 0.064 0.216 0.008 0.084 0.552 0.080 0.410 
FBG (mmol/L) -0.119 0.174 0.243 0.223 -0.278 0.408 -0.243 0.196  -0.090 0.054 0.019 0.816 -0.351 0.010 -0.144 0.136 
2 hr BG (mmol/L) -0.222 0.012 0.001 0.995 -0.109 0.749 NA NA  -0.121 0.010 -0.148 0.073 -0.187 0.184 NA NA 
HbA1c) (%) -0.066 0.455 0.088 0.662 -0.018 0.958 -0.354 0.051  -0.109 0.020 -0.031 0.707 -0.348 0.011 -0.106 0.272 
FBI (mIU/L) -0.048 0.587 0.310 0.124 -0.736 0.010 0.025 0.892  -0.137 0.004 -0.158 0.056 -0.171 0.220 -0.039 0.688 
2 hr BI (mIU/L) -0.122 0.171 0.045 0.825 -0.591 0.056 NA NA  -0.094 0.049 -0.153 0.066 0.322 0.022 NA NA 
Glucose/Insulin ratio 0.029 0.745 -0.310 0.132 0.707 0.022 -0.106 0.578  0.121 0.010 0.162 0.049 0.022 0.880 -0.043 0.658 
HOMA-IR -0.075 0.397 0.301 0.135 -0.600 0.051 -0.080 0.676  -0.141 0.003 -0.155 0.061 -0.268 0.052 -0.147 0.128 
Triglycerides (mmol/L) -0.134 0.125 -0.112 0.580 -0.436 0.180 0.130 0.486  -0.092 0.050 -0.235 0.004 0.124 0.378 -0.323 0.001 
HDL-C (mmol/L) 0.064 0.465 -0.390 0.044 0.537 0.109 -0.052 0.786  0.132 0.005 0.051 0.541 0.164 0.239 0.116 0.230 
LDL-C (mmol/L) -0.146 0.097 0.171 0.394 0.042 0.907 -0.173 0.361  -0.092 0.049 -0.211 0.010 -0.116 0.410 -0.349 <0.001 
Cholesterol (mmol/L) -0.110 0.208 0.121 0.548 -0.064 0.852 -0.223 0.228  -0.068 0.145 -0.175 0.033 -0.083 0.555 -0.315 0.001 
Cholesterol/HDL ratio -0.212 0.015 0.317 0.107 -0.347 0.327 -0.035 0.853  -0.183 0.000 -0.198 0.016 -0.198 0.154 -0.390 0.000 
Gamma GT-S (IU/L) -0.045 0.606 0.021 0.917 0.264 0.433 0.110 0.557  0.052 0.266 -0.056 0.498 0.058 0.678 0.034 0.726 
Creatinine-S (umol/L) 0.016 0.859 0.083 0.680 -0.041 0.905 0.448 0.012  0.018 0.700 0.104 0.208 0.178 0.206 -0.008 0.938 
Creatinine-U (mmol/L) -0.050 0.572 0.160 0.435 0.510 0.109 -0.157 0.399  -0.125 0.008 -0.067 0.422 0.086 0.546 -0.037 0.706 
ALT (SGPT) (IU/L) 0.107 0.224 0.360 0.065 -0.073 0.831 -0.208 0.262  -0.053 0.257 -0.021 0.801 0.241 0.083 0.149 0.121 
AST (SGOT) (IU/L) 0.133 0.131 0.468 0.468 0.174 0.610 0.140 0.451  0.021 0.649 -0.022 0.789 0.150 0.285 0.226 0.019 
MDRD 
(mL/min/1.73m2) -0.052 0.557 0.093 0.646 -0.068 0.851 -0.412 0.024  0.012 0.801 -0.024 0.774 -0.112 0.431 0.009 0.927 
Parathormone (pmol/L) -0.132 0.133 -0.292 0.139 -0.200 0.555 -0.105 0.574  -0.186 <0.001 -0.182 0.027 -0.277 0.047 -0.017 0.864 
Albumin-S (g/L) 0.070 0.422 -0.054 0.789 0.041 0.904 0.054 0.775  0.136 0.004 0.042 0.608 0.173 0.214 0.193 0.045 
Calcium-S (mmol/L) 0.135 0.122 0.109 0.590 0.301 0.368 0.297 0.105  0.182 <0.001 0.001 0.989 0.098 0.486 0.127 0.189 
Phosphate-S (mmol/L) 0.008 0.931 -0.095 0.636 -0.082 0.811 -0.050 0.790  0.068 0.150 0.054 0.520 0.201 0.148 0.056 0.563 
Sodium-U (mmol/L)  -0.065 0.461 -0.093 0.653 0.318 0.340 -0.152 0.415  -0.014 0.771 0.050 0.548 -0.187 0.188 0.227 0.021 
CRP (mg/L) -0.119 0.174 -0.080 0.693 0.145 0.670 -0.146 0.433  -0.081 0.085 -0.113 0.173 -0.134 0.338 -0.012 0.905 
Cotinine (ng/mL) 0.097 0.267 -0.064 0.751 -0.063 0.854 0.163 0.381  0.070 0.136 0.144 0.080 0.217 0.119 -0.100 0.303 
*Pearson Chi-square  
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Figure 5.4: Summary of the results of serum VDBP (µg/mL) levels, categorized by 
gender and vitamin D status. 
 
Figure 5. 4: There were significant differences in the serum VDBP (µg/mL) levels 
between the genders (P=0.0030) as well as between the Vitamin D (25(OH)D ng/mL) 
categories, with the  Vitamin D (25(OH)D ng/mL) deficient group displaying a marked 
decrease in Vitamin D BP (µg/mL) levels (P=0.0455), In males, in the Vitamin D 
optimal category, serum VDBP (µg/mL) was 309.4±80.5 (N38), in the insufficient 
category 311.4±72.9 (N90) and in the deficient category 297.9±71.3 (N72). In females, 
the, serum VDBP (µg/mL) was respectively 335.7±71.5 (N88), 331.4±87.8 (N319) and 
313.2±75.5 (N358) (µg/mL). [Even though the serum VDBP (µg/mL) was decreased 
in the Vitamin D deficiency group in both genders, the serum VDBP (µg/mL) showed 
levels (mean±SD) well within the reference range for normal values in all the Vitamin 
D categories and for both genders, The reference range for serum VDBP (µg/mL) from 
healthy volunteers has been reported to be 253± 51.3 (mean±SD) and 168-367 
(range) (µg/mL) according to the Human Vitamin D BP Quantikine ELISA kit (DVDBP0; 
R&D Systems, Minneapolis, MN, USA).
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5.5 The correlation of serum Vitamin D BP (µg/mL) with anthropometric 
and biochemical measurements categorized by to gender. 
There were no significant correlations between serum VDBP (µg/mL)) and any of the 
anthropometric measurements in either gender. serum VDBP (µg/mL) showed a 
significant positive correlation with Vitamin D (25(OH)D ng/mL) in females (R=0.0969, 
P=0.0073), but not in males. Serum VDBP (µg/mL) showed weak near-significant 
positive correlations with 2 hr BG (mmol/L), HbA1c) (%) and HOMA-IR (All, 
P>0.05≤0.10) and significant positive correlations with FBI (mIU/L) and 2 hr BI (mIU/L) 
(All, P≤0.0356), but not in male subjects with any of the glycaemic measurements. 
Serum VDBP (µg/mL) showed a significant positive correlation with the Triglycerides 
(mmol/L) in female subjects (P<0.0001) but not in male subjects, while serum VDBP 
(µg/mL) showed significant positive correlations with LDL -C (mmol/L), Cholesterol 
(mmol/L) and Gamma GT-S (IU/L) (P≤0.0016) in male subjects, but not in female 
subjects. serum VDBP (µg/mL) showed a significant positive correlation in females 
(R=0.0578, P=0.0448) and a near-significant positive correlation in males (R=0.0883, 
P=0.0836) with Creatinine-S (umol/L). serum VDBP (µg/mL) showed a significant 
inverse correlation with AST (SGOT) (IU/L) in female subjects (R=-0.0754, P=0.0087). 
serum VDBP (µg/mL) showed significant positive correlations with the CRP (mg/L) in 
both males (R=0.1689, P=0.0009) and females (R=0.0831, P=0.0038).





Table 5.5: The correlation of serum Vitamin D BP (µg/mL) with anthropometric and biochemical measurements categorized 
by gender. 
 Total, N=1598 Males, N=385 Females, N=1213 
 R P-value R P-value R P-value 
Age (years) 0.0402 0.1082 0.0618 0.2263 0.0264 0.3590 
Anthropometric measurements       
BMI (kg/m2) -0.0050 0.8435 -0.0184 0.7195 -0.0550 0.0558 
Waist (cm) 0.0256 0.3073 0.0430 0.4007 -0.0107 0.7094 
Hip (cm) 0.0160 0.5241 0.0212 0.6787 -0.0362 0.2085 
WHR 0.0450 0.0725 0.0594 0.2456 0.0557 0.0527 
Biochemical measurements       
Vitamin D (25(OH)D ng/mL) 0.0808 0.0120 0.0767 0.2802 0.0969 0.0073 
FBG (mmol/L) -0.0025 0.9212 -0.0442 0.3882 0.0005 0.9871 
2 hr BG (mmol/L) 0.0513 0.0578 -0.0269 0.6242 0.0561 0.0711 
HbA1c) (%) 0.0537 0.0326 0.0235 0.6476 0.0504 0.0800 
FBI (mIU/L) 0.0672 0.0078 0.0078 0.8791 0.0610 0.0356 
2 hr BI (mIU/L) 0.0858 0.0017 0.0426 0.4390 0.0754 0.0169 
Glucose/Insulin ratio -0.0654 0.0106 -0.0047 0.9289 -0.0620 0.0346 
HOMA-IR 0.0582 0.0214 -0.0063 0.9029 0.0543 0.0614 
Triglycerides (mmol/L) 0.1208 <0.0001 0.0790 0.1243 0.1283 <0.0001 
HDL-C (mmol/L) 0.0127 0.6117 0.0461 0.3692 -0.0116 0.6855 
LDL-C (mmol/L) 0.0760 0.0024 0.1607 0.0016 0.0307 0.2863 
Cholesterol (mmol/L) 0.0844 0.0007 0.1762 0.0005 0.0350 0.2228 
Cholesterol/HDL ratio 0.0661 0.0089 0.0927 0.0732 0.0512 0.0768 
Gamma GT-S (IU/L) 0.0741 0.0030 0.2182 <0.0001 0.0418 0.1452 
Creatinine-S (umol/L) 0.0074 0.7684 0.0883 0.0836 0.0578 0.0448 
Creatinine-U (mmol/L) -0.0726 0.0249 -0.0059 0.9346 -0.0700 0.0543 
ALT (SGPT) (IU/L) -0.0394 0.1156 0.0072 0.8876 -0.0402 0.1621 
AST (SGOT) (IU/L) -0.0774 0.0020 -0.0229 0.6552 -0.0754 0.0087 
MDRD (mL/min/1.73m2) -0.0683 0.0069 -0.0953 0.0641 -0.0535 0.0652 
Parathormone (pmol/L) 0.0217 0.4992 0.0092 0.8970 0.0019 0.9581 
Albumin-S (g/L) 0.0011 0.9735 0.0637 0.3699 0.0078 0.8296 
Calcium-S (mmol/L) 0.0494 0.1211 0.0267 0.7036 0.0591 0.0984 
Phosphate-S (mmol/L) -0.0247 0.4397 0.0832 0.2357 -0.0686 0.0558 
Sodium-U (mmol/L)  0.0041 0.9002 0.0921 0.1958 -0.0039 0.9151 
CRP (mg/L) 0.1136 <0.0001 0.1689 0.0009 0.0831 0.0038 
Cotinine (ng/mL) -0.0171 0.4981 0.0325 0.5303 -0.0187 0.5196 
*Pearson Chi-square   
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5.6 The correlation of serum Vitamin D BP (µg/mL) with anthropometric 
and biochemical measurements categorized by gender and glycaemic 
status. 
Serum VDBP (µg/mL) showed very few significant correlations in both genders and all 
glycaemic sub-groups with both anthropometric and biochemical measurements. 
Serum VDBP (µg/mL) correlated near-significantly inversely with the BMI (kg/m2) in 
normo-glycaemic females (P=0.089) and significantly inversely with the BMI (kg/m2) 
(P=0.019), the Waist C (cm) (P=0.027) and near-significantly inversely with the Hip C 
(cm) (P=0.068) in pre-DM females, while in contrast near-significantly positively with 
the Waist C (cm) (P=0.101) in normo-glycaemic male subjects. Serum VDBP (µg/mL) 
showed near-significant positive correlations with 2 hr BG (mmol/L) and 2 hr BI (mIU/L) 
in normo-glycaemic female subjects (All, P≤0.084) and significant positive correlations 
with FBI (mIU/L) and 2 hr BI (mIU/L) in screen-detected DM female subjects (All, 
P≤0.040). In males, serum VDBP (µg/mL) showed a near-significant positive 
correlation with HbA1c) (%) in normo-glycaemic male subjects (P=0.097) and a 
significant inverse correlation with 2 hr BG (mmol/L) in pre-DM male subjects 
(P=0.011). 
 serum VDBP (µg/mL) showed significant positive correlations with the triglycerides 
(mmol/L) in Normo-glycaemic and in Pre-DM female subjects (All, P≤0.013). Serum 
VDBP (µg/mL) showed no correlation with the lipids in any of the glycaemic sub-
groups in females, but significant positive correlations with LDL-C (mmol/L) and 
Cholesterol (mmol/L) in normo-glycaemic males (All, P≤0.002) and a significant 
positive correlation with HDL-C (mmol/L) (P=0.018) and a near-significant positive 
correlation with Cholesterol (mmol/L) (P=0.103) in screen-detected DM males. serum 
VDBP (µg/mL) showed significant positive correlations with Gamma GT-S (IU/L) in 
normo-glycaemic (R=0.231, P<0.001), screen-detected DM (R=0.706, P=0.0020) and 
a near-significant positive correlation in known DM (R=0.269, P=0.067) male subjects, 
but none in the female subjects. serum VDBP (µg/mL) showed significant positive 
correlations with the CRP (mg/L) in both male (R=0.218, P<0.001) and female 
(R=0.076, P=0.038) normo-glycaemic subjects. 
 





Table 5.6: The correlation of serum Vitamin D BP (µg/mL) with anthropometric and biochemical measurements categorized 
by gender and glycaemic status. 





































Age (years) 0.110 0.065 -0.059 0.714 -0.166 0.538 0.217 0.143  -0.005 0.900 -0.007 0.925 0.037 0.741 0.162 0.035 
Anthropometric measurements                  
BMI (kg/m2) 0.028 0.639 -0.094 0.565 0.057 0.833 -0.099 0.509  -0.062 0.089 -0.163 0.019 -0.002 0.984 0.030 0.702 
Waist C (cm) 0.098 0.101 -0.020 0.902 0.100 0.713 0.003 0.986  -0.012 0.738 -0.155 0.027 0.020 0.859 0.090 0.245 
Hip C (cm) 0.036 0.548 0.048 0.767 0.126 0.641 0.008 0.957  -0.032 0.385 -0.128 0.068 0.006 0.959 -0.012 0.879 
WHR 0.123 0.040 -0.080 0.621 -0.091 0.736 0.070 0.640  0.028 0.446 -0.006 0.937 -0.054 0.630 0.244 0.001 
Biochemical measurements                 
Vitamin D (25(OH)D ng/mL) 0.023 0.791 0.037 0.856 0.539 0.108 0.116 0.535  0.087 0.064 0.216 0.008 0.084 0.552 0.080 0.410 
FBG (mmol/L) 0.010 0.861 -0.111 0.491 0.076 0.778 -0.161 0.286  -0.013 0.724 -0.060 0.390 -0.087 0.434 -0.055 0.480 
2 hr BG (mmol/L) 0.015 0.810 -0.393 0.011 0.082 0.762 NA NA  0.069 0.059 0.025 0.726 -0.051 0.654 NA NA 
HbA1c) (%) 0.100 0.097 -0.043 0.789 0.069 0.799 -0.016 0.913  0.058 0.114 0.028 0.688 -0.060 0.592 0.028 0.716 
FBI (mIU/L) 0.039 0.519 -0.024 0.887 -0.076 0.778 -0.076 0.614  0.036 0.322 0.034 0.636 0.229 0.040 0.028 0.722 
2 hr BI (mIU/L) 0.066 0.278 0.043 0.790 -0.143 0.612 NA NA  0.064 0.084 0.032 0.654 0.303 0.007 NA NA 
Glucose/Insulin ratio -0.030 0.620 0.014 0.934 0.132 0.638 0.086 0.578  -0.047 0.210 -0.034 0.635 -0.338 0.003 -0.044 0.576 
HOMA-IR 0.046 0.451 -0.036 0.827 0.015 0.957 -0.136 0.367  0.037 0.318 0.019 0.792 0.151 0.182 -0.006 0.943 
Triglycerides (mmol/L) 0.088 0.146 0.147 0.358 0.203 0.451 0.147 0.326  0.109 0.003 0.172 0.013 0.160 0.149 0.100 0.198 
HDL-C (mmol/L) 0.052 0.384 -0.195 0.221 0.600 0.018 0.053 0.725  -0.007 0.845 -0.031 0.657 0.036 0.743 -0.021 0.783 
LDL-C (mmol/L) 0.188 0.002 0.084 0.602 0.262 0.346 0.121 0.422  -0.009 0.812 0.129 0.065 0.125 0.261 0.033 0.670 
Cholesterol (mmol/L) 0.202 0.001 0.006 0.968 0.422 0.103 0.137 0.358  -0.002 0.956 0.120 0.088 0.134 0.226 0.029 0.710 
Cholesterol/HDL ratio 0.093 0.125 0.225 0.157 -0.055 0.845 0.063 0.679  0.011 0.766 0.162 0.021 0.103 0.359 0.026 0.743 
Gamma GT-S (IU/L) 0.231 <0.001 -0.009 0.953 0.706 0.002 0.269 0.067  0.042 0.252 0.023 0.747 -0.037 0.739 0.106 0.170 
Creatinine-S (umol/L) 0.056 0.352 0.013 0.935 0.041 0.879 0.436 0.002  0.011 0.755 0.135 0.054 0.198 0.074 0.090 0.244 
Creatinine-U (mmol/L) 0.007 0.934 -0.318 0.113 0.699 0.024 -0.026 0.891  -0.115 0.014 0.087 0.295 -0.254 0.072 -0.020 0.839 
ALT (SGPT) (IU/L) 0.010 0.865 0.071 0.658 0.299 0.261 -0.188 0.206  -0.021 0.572 -0.158 0.024 -0.156 0.158 0.054 0.487 
AST (SGOT) (IU/L) -0.040 0.504 0.010 0.948 0.251 0.349 -0.090 0.547  -0.024 0.516 -0.150 0.032 -0.277 0.012 -0.054 0.489 
MDRD (mL/min/1.73m2) -0.039 0.513 -0.038 0.814 -0.073 0.797 -0.540 <0.001  0.005 0.900 -0.125 0.076 -0.166 0.136 -0.108 0.165 
Parathormone (pmol/L) 0.045 0.610 -0.147 0.464 0.115 0.751 0.034 0.854  -0.006 0.901 -0.048 0.561 0.215 0.119 0.009 0.929 
Albumin-S (g/L) 0.055 0.531 0.137 0.497 -0.251 0.485 0.058 0.755  -0.066 0.156 0.167 0.043 0.141 0.314 0.049 0.616 
Calcium-S (mmol/L) 0.057 0.509 -0.017 0.934 0.207 0.565 -0.157 0.391  0.056 0.226 -0.011 0.898 0.136 0.313 0.095 0.325 
Phosphate-S (mmol/L) 0.030 0.729 0.002 0.992 0.321 0.365 0.229 0.207  -0.092 0.047 -0.001 0.990 -0.266 0.046 0.005 0.956 
Sodium-U (mmol/L)  0.068 0.438 0.004 0.985 0.515 0.128 -0.038 0.840  -0.016 0.736 -0.026 0.752 0.058 0.687 0.040 0.690 
CRP (mg/L) 0.218 <0.001 -0.237 0.135 0.024 0.931 0.281 0.056  0.076 0.038 0.099 0.157 0.045 0.686 0.096 0.214 
Cotinine (ng/mL) -0.038 0.534 0.153 0.341 -0.030 0.913 0.300 0.043  -0.005 0.884 -0.022 0.751 -0.009 0.936 -0.051 0.512 
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*Pearson Chi-square  
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5.7 Hardy-Weinberg Equilibrium. 
Hardy-Weinberg equilibrium (HWE) principle states that allele and genotype 
frequencies in a population will remain constant from generation to generation in the 
absence of other evolutionary influences. In the present study, Fok1, Apa1, Taq1 
SNPs were consistent with the Hardy-Weinberg equilibrium (HWE), respectively Chi-
squared (X2), frequency range for the p Allele and for the q Allele for SNP Fok1 
(rs2228570):  3.0917, 0.7445 and 0.2555; for SNP Apa1 (rs7975232) respectively 
2.9729, 0.6142 and 0.3858;and for SNP Taq1 (rs731236) respectively 0.0157, 0.7174 
and 0.2826 [The total number of participants tested was 1603]. The Frequency of 
variant allele C of the Fok1 SNP was similar in both normo-glycaemic and hyper-
glycaemic groups. There was no significant difference in the variant genotypes’ 
distribution between normo-glycaemic and hyper-glycaemic groups (see Table 5.10).  
Also, variant allele A of the Apa1 and T of the Taq1 were similar amongst normo-
glycaemic and Hyper-glycaemic groups. The genotype frequencies distribution of 
these SNPs was similar and not associated with T2DM.





Table 5.7: Hardy-Weinberg Equilibrium testing. 
       
  Genotype Observed no  Expected no Chi-squared (chi2) p Allele frequency q Allele frequency 
SNP Fok1 
rs2228570  Common Homozygotes GG 902 888.6    
 Heterozygotes AG 583 609.8    
 Rare Homozygotes AA 118 104.6    
     3.0917 0.7445 0.2555 
        
SNP Apa1 
rs7975232  Common Homozygotes AA 621 604.6    
 Heterozygotes AC 727 759.7    
 Rare Homozygotes CC 255 238.6    
     2.9729 0.6142 0.3858 
        
SNP Taq1 
rs731236  Common Homozygotes AA 824 825.0    
 Heterozygotes AG 652 650.0    
 Rare Homozygotes GG 127 128.0    
     0.0157 0.7174 0.2826 
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5.8 The genotype and allele frequency of (Fok1 rs2228570), Apa1 
(rs7975232), and Taq1 (rs731236) SNPs categorized by gender. 
As summarized in Table 5.8, there was no significance difference in the genotype or 
allele frequency distribution of Fok1 (rs2228570), Apa1 (rs7975232) or Taq1 
(rs731236) SNPs in both males and females (P≥0.2864 and P≥0.6347 respectively).





Table 5.8: The genotype and allele frequency of (Fok1 rs2228570), Apa1 (rs7975232), and Taq1 (rs731236) SNPs 
categorized by gender. 
  Total Males Females    
 Genotype    Chi-square* df P-value 
SNP Fok1 rs2228570 GG 56.3% (902/1603)  55.3% (214/387) 56.6% (688/1216)     
 AG 36.4% (583/1603) 37.7% (146/387)  35.9% (437/1216)     
 AA 7.4% (118/1603)  7.0% (27/387)  7.5% (91/1216)    
     0.4463 2 0.8000 
 Allele       
 G 74.5% (2387/3206) 74.2% (574/774) 74.5% (1813/2432)    
 A 25.5% (819/3206) 25.8% (200/774) 25.5% (619/2432)    
     0.0000 1 0.9668 
        
SNP Apa1 rs7975232 AA 38.7% (621/1603) 36.7% (142/387) 39.4% (479/1216)    
 AC 45.4% (727/1603) 47.3% (183/387) 44.7% (544/1216)    
 CC 15.9% (255/1603) 16.0% (62/387) 15.9% (193/1216)    
     0.9770 2 0.6136 
 Allele       
 A 61.4% (1969/3206) 60.3% (467/774) 61.8% (1502/2432)    
 C 38.6% (1237/3206) 39.7% (307/774) 38.2% (930/2432)    
     0.0800 1 0.7719 
        
SNP Taq1 rs731236 AA 51.4% (824/1603) 53.7% (208/387) 50.7% (616/1216)    
 AG 40.7% (652/1603) 40.1% (155/387) 40.9% (497/1216)    
 GG 7.9% (127/1603) 6.2% (24/387) 8.5% (103/1216)    
     2.5009 2 0.2864 
 Allele       
 A 71.7% (2300/3206) 73.8% (571/774) 71.1% (1729/2432)    
 G 28.3%  (906/3206) 26.2% (203/774) 28.9% (703/2432)    
     0.2300 1 0.6347 
        
*Pearson Chi-square,  
*2 x 2 Table, Chi-square
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5.9 The genotype and allele frequency of (Fok1 rs2228570), Apa1 
(rs7975232), and Taq1 (rs731236) SNPs categorized by gender 
categorized by obesity status. 
As summarized in Table 5.9, there was no significance difference in the genotype or 
allele frequency distribution of Fok1 (rs2228570), Apa1 (rs7975232) or Taq1 
(rs731236) SNPs in both normal weight and overweight/obese patients (P≥0.1647 and 
P≥0.7471 respectively).





Table 5.9: The genotype and allele frequency of (Fok1 rs2228570), Apa1 (rs7975232), and Taq1 (rs731236) SNPs 
categorized by gender categorized by obesity status. 
  Total Normal weight Overweight/obese    
 Genotype    Chi-square* df P-value 
SNP Fok1 rs2228570 GG 56.3% (898/1596) 53.8% (282/524) 57.5% (616/1072)    
 AG 36.3% (580/1596) 39.1% (205/524) 35.0% (375/1072)    
 AA 7.4% (118/1596) 7.1% (37/524) 7.6% (81/1072)    
     2.6087 2 0.2714 
 Allele       
 G 74.4% (2376/3192) 73.4% (769/1048) 75.0% (1607/2144)    
 A 25.6% (816/3192) 26.6% (279/1048) 25.0% (537/2144)    
     0.1000 1 0.7471 
        
SNP Apa1 rs7975232 AA 38.7% (617/1596) 36.8% (193/524) 39.6% (424/1072)    
 AC 45.4% (724/1596) 48.7% (255/524) 43.8% (469/1072)    
 CC 16.0% (255/1596) 14.5% (76/524) 16.7% (179/1072)    
     3.6076 2 0.1647 
 Allele       
 A 61.3% (1958/3192) 61.2% (641/1048) 61.4% (1317/2144)    
 C 38.7% (1234/3192) 38.8% (407/1048) 38.6% (827/2144)    
     0.0000 1 1.0000 
        
SNP Taq1 rs731236 AA 51.5% (822/1596) 51.3% (269/524) 51.6% (553/1072)    
 AG 40.5% (647/1596) 41.6% (218/524) 40.0% (429/1072)    
 GG 8.0% (127/1596) 7.1% (37/524) 8.4% (90/1072)    
     1.0099 2 0.6036 
 Allele       
 A 71.8% (2291/3192) 72.1% (756/1048) 71.6% (1535/2144)    
 G 28.2% (901/3192) 27.9% (292/1048) 28.4% (609/2144)    
     0.0000 1 1.0000 
        
*Pearson Chi-square 
*2 x 2 Table, Chi-square.
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5.10 The genotype and allele frequency of (Fok1 rs2228570), Apa1 
(rs7975232), and Taq1 (rs731236) SNPs categorized by glycaemic 
status. 
As summarized in Table 5.10, there was no significance difference in the genotype or 
allele frequency distribution of Fok1(rs2228570), Apa1 (rs7975232) or Taq1 
(rs731236) SNPs in both normo-glycaemic and hyper-glycaemic patients (P≥0.1670 
and P≥0.8711 respectively). 
 





Table 5.10: The genotype and allele frequency of (Fok1 rs2228570), Apa1 (rs7975232), and Taq1 (rs731236) SNPs 
categorized by glycaemic status. 
  Total Normo-glycaemia Hyper-glycaemia    
 Genotype    Chi-square* df P-value 
SNP Fok1 rs2228570 GG 56.3% (902/1603)  55.1% (572/1039) 58.5% (330/564)    
 AG 36.4% (583/1603) 37.7% (392/1039) 33.9% (191/564)    
 AA 7.4% (118/1603)  7.2% (75/1039) 7.6% (43/564)    
     2.3586 2 0.3075 
 Allele       
 G 74.5% (2387/3206) 73.9% (1536/2078) 75.4% (851/1128)    
 A 25.5% (819/3206) 26.1% (542/2078) 24.6% (277/1128)    
     0.0300 1 0.8711 
        
SNP Apa1 rs7975232 AA 38.7% (621/1603) 38.0% (395/1039) 40.1% (226/564)    
 AC 45.4% (727/1603) 47.0% (488/1039) 42.4% (239/564)    
 CC 15.9% (255/1603) 15.0% (156/1039) 17.6% (99/564)    
     3.5790 2 0.1670 
 Allele       
 AA  61.4% (1969/3206) 61.5% (1278/2078) 61.3% (691/1128)    
 CC 38.6% (1237/3206) 38.5% (800/2078) 38.7% (437/1128)    
     0.0000 1 0.9552 
        
SNP Taq1 rs731236 AA 51.4% (824/1603) 52.2% (542/1039) 50.0% (282/564)    
 AG 40.7% (652/1603) 39.4% (409/1039) 43.1% (243/564)    
 GG 7.9% (127/1603) 8.5% (88/1039) 6.9% (39/564)    
     2.6929 2 0.2602 
 Allele       
 A  71.7% (2300/3206)  71.8% (1493/2078) 71.5% (807/1128)    
 G 28.3% (906/3206)  28.2% (585/2078)  28.5% (321/1128)    
     0.0100 1 0.9107 
        
*Pearson Chi-square 
*2 x 2 Table, Chi-square
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5.11 The genotype and allele frequency of (Fok1 rs2228570), Apa1 
(rs7975232), and Taq1 (rs731236) SNPs categorized by insulin 
resistance (HOMA-IR) status. 
As summarized in Table 5.11, There was no significant difference in the frequency of 
Fok1 (rs2228570) SNP between subjects with normal insulin resistance and those with 
moderate/severe insulin resistance, but a near-significant and significant difference in 
the frequency of Apa1 (rs7975232) and Taq1 (rs731236) SNPs existed between 
subjects with normal and those with moderate/severe insulin resistance (P=0.0797 
and P=0.0360 respectively), but not in their allele frequencies.





Table 5.11: The genotype and allele frequency of (Fok1 rs2228570), Apa1 (rs7975232), and Taq1 (rs731236) SNPs 
categorized by insulin resistance (HOMA-IR) status. 
  Total Normal IR Moderate/severe IR    
 Genotype    Chi-square* df P-value 
SNP Fok1 rs2228570 GG 56.1% (880/1568) 54.8% (653/1191) 60.2% (227/377)    
 AG 36.7% (576/1568) 38.0% (452/1191) 32.9% (124/377)    
 AA 7.1% (112/1568) 7.2% (86/1191) 6.9% (26/377)    
     3.5173 2 0.1723 
 Allele       
 G  74.5% (2336/3136) 73.8% (1758/2382) 76.7% (578/754)    
 A 25.5% (800/3136) 26.2% (624/2382) 23.3% (176/754)    
     0.2400 1 0.6219 
        
SNP Apa1 rs7975232 AA 38.8% (608/1568) 37.7% (449/1191) 42.2% (159/377)    
 AC 45.5% (713/1568) 47.3% (563/1191) 39.8% (150/377)    
 CC 15.8% (247/1568) 15.0% (179/1191) 18.0% (68/377)    
     6.6505 2 0.0360 
 Allele       
 A 61.5% (1929/3136) 61.3% (1461/2382) 62.1% (468/754)    
 C 38.5% (1207/3136) 38.7% (921/2382) 37.9% (286/754)    
     0.0200 1 0.8845 
        
SNP Taq1 rs731236 AA 51.3% (804/1568) 52.1% (621/1191) 48.5% (183/377)    
 AG 40.8% (639/1568) 40.7% (485/1191) 40.8% (154/377)    
 GG 8.0% (125/1568) 7.1% (85/1191) 10.6% (40/377)    
     5.0581 2 0.0797 
 Allele       
 A  71.7% (2247/3136)  72.5% (1727/2382) 69.0% (520/754)    
 G 28.3% (889/3136)  27.5% (655/2382) 31.0% (234/754)    
     0.2600 1 0.6100 
        
*Pearson Chi-square 
*2 x 2 Table, Chi-square
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5.12 The genotype and allele frequency of SNPs (Fok1 rs2228570), 
Apa1 (rs7975232), and Taq1 (rs731236), categorized by Vitamin D 
(25(OH)D ng/mL) status. 
As summarized in Table 5.12, there was no significance difference in the genotype or 
allele frequency distribution of Fok1 (rs2228570), Apa1 (rs7975232) or Taq1 
(rs731236) SNPs between subjects with optimal Vitamin D (25(OH)D ng/mL) levels 
and those with insufficient/deficient levels (P≥0.2036 and P≥0.6347 respectively). 
There was no association between the studied SNPs genotypes/ alleles and vitamin 
D deficiency.





Table 5.12: The genotype and allele frequency of SNPs (Fok1 rs2228570), Apa1 (rs7975232), and Taq1 (rs731236), 
categorized by Vitamin D (25(OH)D ng/mL) status. 
  Total Optimal Vitamin D levels 
Insufficient/ deficient 
Vitamin D levels    
 Genotype    Chi-square* df P-value 
SNP Fok1 rs2228570 GG 55.0% (532/968) 54.8% (69/126) 55.0% (463/842)    
 AG 37.0% (358/968) 33.3% (42/126) 37.5% (316/842)    
 AA 8.1% (78/968) 11.9% (15/126) 7.5% (63/842)    
     3.1832 2 0.2036 
 Allele       
 G  73.5% (1422/1936)  71.4% (180/252)  73.8% (1242/1684)    
 A 26.5% (514/1936)  28.6% (72/252)  26.2% (442/1684)    
     0.2300 1 0.6347 
        
SNP Apa1 rs7975232 AA 38.9% (377/968) 38.9% (49/126) 39.0% (328/842)    
 AC 44.0% (426/968) 42.9% (54/126) 44.2% (372/842)    
 CC 17.0% (165/968) 18.3% (23/126) 16.9% (142/842)    
     0.1679 2 0.9195 
 Allele       
 A  61.0% (1180/1936)  60.3% (152/252) 61.0% (1028/1684)    
 C 39.0% (756/1936)  39.7% (100/252) 39.0% (656/1684)    
     0.0200 1 0.8850 
        
SNP Taq1 rs731236 AA 50.2% (486/968) 54.0% (68/126) 49.6% (418/842)    
 AG 41.7% (404/968) 38.9% (49/126) 42.2% (355/842)    
 GG 8.1% (78/968) 7.1% (9/126) 8.2% (69/842)    
     0.8400 2 0.6570 
 Allele       
 A 71.1% (1376/1936)  73.4% (185/252) 70.7% (1191/1684)    
 G 28.9% (560/1936) 26.6% (67/252) 29.3% (493/1684)    
     0.1000 1 0.7528 
        
*Pearson Chi-square 
*2 x 2 Table, Chi-square
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5.13 The results for serum VDBP(µg/mL) according to SNPs 
Fok1 (rs2228570), Apa1 (rs7975232) and Taq1 (rs731236) 
genotypes. 
As summarized below in Table 5.13, there was no significance differences in the 
serum VDBP levels as evaluated against SNPs Fok1 (rs2228570), Apa1 (rs7975232) 
and Taq1 (rs731236 genotypes). These results demonstrate no association between 
SNPs genotypes and serum VDBP levels.





Table 5.13: Vitamin D binding protein (µg/mL) according to SNPs Fok1 (rs2228570), Apa1 (rs7975232) and Taq1 
(rs731236) genotypes. 
  Vitamin D binding protein (µg/mL)  
  Mean ± SD P-value 
SNP Fok1 rs2228570 Genotype GG AG AA  
  310.4±76.1 313.5±74.2 314.6±74.5 0.6787 
      
      
  Mean ± SD P-value 
SNP Apa1 rs7975232 Genotype AA AC CC  
  310.0±71.9 313.1±79.5 312.8±71.0 0.7392 
      
  Mean ± SD P-value 
SNP Taq1 rs731236 Genotype AA AG GG  
  311.3±74.5 312.8±76.4 310.4±74.7 0.9009 
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5.14 Multiple Linear regression analysis for dependent variable Vitamin 
D (25(OH)D ng/mL). 
Multiple linear regression analysis revealed that Age, serum VDBP levels and 
creatinine were predictors of vitamin D levels in females of the total population group 
and the hyper-glycaemic female group. In hyper-glycaemic females, only triglycerides 
remained predictors of vitamin D levels. In the total group LDL-C was a predictor of 
vitamin D levels in both males and females, but in the glycaemic group statistical 
significance was observed in the hyper-glycaemic females not males. PTH levels were 
predictors of vitamin D levels in both males and glycaemic groups except in normo-
glycaemic male group.  All other variables did not reach statistical significance in either 
males and females of the total group and the glycaemic sub-groups. In normo-
glycaemic males 19.5% variation in 25(OH)D was attributed by increased LDL-C and 
in the hyper-glycaemic group 15.5% it was attributed by PTH and CRP. In normo-
glycaemic 12.8% variation in 25(OH)D was attributed by LDL-C, serum Creatinine and 
PTH, whereas in hyper-glycaemic group 16.1% was attributed by increased age, 
serum VDBP, triglycerides, LDL-C, creatinine and PTH. Results of the regression 
analysis are summarised below on table 5.13. 






Table 5.14: Multiple linear regression analysis for dependent variable Vitamin D (25-(OH)D ng/mL). 




















Adjusted R² 0.149 (14.9%) 0.175 (17.5%) 0.140 (14.0%) 0.195 (19.5%) 0.155 (15.5%) 0.128 (12.8%) 0.161 (16.1%) 
Age (years) 0.072 0.048 -0.037 0.675 0.105 0.014 -0.036 0.763 0.250 0.192 0.092 0.143 0.160 0.010 
BMI (kg/m2) -0.033 0.380 0.013 0.875 -0.065 0.123 -0.111 0.310 0.362 0.072 -0.038 0.509 -0.050 0.432 
Serum VDBP  (µg/mL) 0.090 0.004 0.031 0.665 0.106 0.003 0.002 0.979 0.226 0.136 0.070 0.144 0.155 0.007 
FBG (mmol/L) -0.060 0.068 -0.032 0.673 -0.067 0.071 -0.082 0.413 -0.083 0.588 -0.074 0.147 -0.023 0.702 
FBI (mIU/L) -0.061 0.074 -0.046 0.573 -0.064 0.099 0.103 0.353 -0.108 0.505 -0.018 0.740 -0.064 0.290 
Triglycerides (mmol/L) -0.105 0.078 -0.102 0.251 -0.097 0.188 -0.141 0.150 -0.223 0.286 0.027 0.631 -0.363 0.016 
HDL-C (mmol/L) 0.036 0.307 -0.088 0.252 0.056 0.176 -0.082 0.394 -0.308 0.051 0.069 0.218 0.027 0.682 
LDL-C (mmol/L) -0.169 <0.001 -0.236 0.004 -0.161 <0.001 -0.233 0.033 -0.181 0.224 -0.164 0.003 -0.169 0.006 
Gamma GT-S (IU/L) 0.060 0.132 0.282 0.008 -0.015 0.745 0.232 0.101 0.153 0.387 -0.016 0.822 0.054 0.420 
Creatinine-S (umol/L) 0.251 <0.001 0.202 0.237 0.350 <0.001 -0.078 0.702 0.701 0.104 0.414 <0.001 0.300 0.016 
Creatinine-U (mmol/L) -0.047 0.134 -0.022 0.754 -0.059 0.099 -0.033 0.709 0.173 0.246 -0.050 0.289 -0.055 0.337 
ALT (SGPT) (IU/L) 0.019 0.708 -0.057 0.667 0.079 0.180 -0.167 0.317 0.127 0.622 -0.012 0.882 0.145 0.118 
AST (SGOT) (IU/L) 0.040 0.473 -0.025 0.876 0.021 0.725 0.136 0.517 -0.191 0.448 0.050 0.567 0.024 0.798 
MDRD (mL/min/1.73m2) 0.066 0.255 -0.172 0.246 0.208 0.006 -0.327 0.098 0.003 0.994 0.198 0.051 0.252 0.033 
Parathormone (pmol/L) -0.275 <0.001 -0.280 0.015 -0.280 <0.001 -0.155 0.104 -0.819 0.024 -0.326 <0.001 -0.240 0.001 
Albumin-S (g/L) 0.069 0.046 0.041 0.695 0.057 0.138 0.074 0.599 -0.107 0.548 0.017 0.766 0.038 0.548 
Calcium-S (mmol/L) 0.031 0.314 0.155 0.122 0.036 0.296 0.208 0.092 -0.177 0.471 0.144 0.010 0.067 0.218 
Phosphate-S (mmol/L) -0.007 0.905 -0.106 0.174 -0.018 0.793 -0.077 0.404 -0.167 0.317 -0.047 0.334 0.154 0.288 
Sodium-U (mmol/L)  -0.046 0.163 -0.092 0.244 -0.029 0.437 -0.076 0.438 -0.103 0.580 -0.026 0.594 -0.047 0.413 
CRP (mg/L) -0.066 0.050 -0.150 0.069 -0.030 0.418 -0.167 0.142 -0.513 0.010 -0.022 0.661 -0.069 0.264 
Cotinine (ng/mL) 0.019 0.566 0.057 0.486 0.015 0.700 -0.035 0.727 0.089 0.580 0.013 0.791 0.038 0.521 
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Chapter 6 Discussion 
Diabetes mellitus has reached epidemic proportions worldwide and is a major public 
health problem. This was a cross-sectional study which was designed to investigate 
the association between 25(OH)D, vitamin D binding proteins and VDR (Fok1, Apa1 
and Taq1) polymorphisms in T2DM patients in the mixed ancestry population group 
residing in Bellville South, Cape Town, South Africa. This population is characterized 
by a high prevalence of T2DM (28%) as previously reported by (Erasmus et al., 2012) 
, hypertension and obesity (Matsha et al., 2013). T2DM is a multifactorial disease 
caused by a complex interaction of genetics and environmental factors (Palomer et 
al., 2008). In the present study vitamin D deficiency (44%) and insufficiency (42.6%) 
were highly prevalent in the population studied with optimal 25(OH)D levels being 
observed in only 13% of subjects. The overall vitamin D status of the whole population 
group was insufficient (22.0±7.6 ng/mL). 
It has been reported that people living in Southern Hemispheres in cities like Cape 
Town and Buenos Aires produce far less vitamin D during the winter months and this 
has been corroborated by the observation of a high prevalence of vitamin D deficiency 
(62.7%)  in black Africans residing in Cape Town, South Africa (Martineau et al., 2011).  
A high prevalence of  vitamin D deficiency (40%) has also  been observed in  Moroccan 
(Abdeltif et al., 2014) and in Caribbean (42%) subjects with T2DM (Vélayoudom-
céphiseet al., 2011).  
In the present study, 25(OH)D levels and VDBP varied according to gender with males 
having higher 25(OH)D levels (P=0.0006) and females with significantly higher serum 
VDBP levels (P<0.0001). In accordance with our observations , (Blanton et al., 2011) 
observed higher serum VDBP levels in healthy females compared to male subjects 
and  Another study from  Belgium reported 10% higher serum VDBP levels in females 
than males (Bolland et al, 2007).  In the present study the vitamin D deficient groups 
in both genders had low serum VDBP levels compared to the optimal vitamin D groups. 
Even though serum VDBP levels were lower in the vitamin D deficient group, they 
were still within the normal range for healthy individuals (168-367µg/mL) as depicted 
in the assay protocol manual used for determination of serum VDBP levels and the  
range (300-600µg/mL) reported by (Blanton et al., 2011) in their study.  





In contrast , a randomized placebo-controlled trial  reported lower 25(OH)D levels 
(P<0.001) and serum VDBP levels (P<0.001) in blacks compared to non-Blacks 
(Ponda et al., 2014). Similarly, (Powe et al., 2011) reported lower serum total 25(OH)D  
and VDBP  levels in Blacks compared to White American subjects respectively. 
Though the results of the present study fall between those reported in Blacks and 
White Americans, they are more comparable with those of Whites than Black 
Americans. 
Furthermore, the present study results showed a positive correlation between 
25(OH)D and serum VDBP levels in females only but not in males. Similarly, lower 
25(OH)D levels were strongly associated with DBP (rho= 0.57, p<0.001) in post-
menarchal and adolescents European Americans and African Americans (Ashraf et 
al., 2014). However, correlation between 25(OH)D  and serum VDBP levels in both 
male and females have been reported in other studies (Bolland et al., 2007) whilst 
others  found no correlation between 25(OH)D levels and serum VDBP in obese 
Caucasians (Holmlund-Suila et al., 2016). Since females had higher serum VDBP 
levels in the present study, then it could be predicted that their 25(OH)D levels would 
also be higher than males. However, most studies that have reported gender 
differences in 25(OH)D with males having  higher levels than females (Bolland et al., 
2007); (Al-Dabhani et al., 2017).  
It has been shown that obesity is one of the risk factors for vitamin D deficiency in 
diverse populations (Iqbal et al., 2017) and both obesity and vitamin D deficiency are 
also considered the risk factors for T2DM. The results of the present showed that 
females were significantly older and obese compared to males, with lower 25(OH)D 
levels being strongly correlated with BMI in females (P<0.0001). Similar to our 
observations a population-based study conducted in Norway reported a strong inverse 
association between low 25(OH)D levels and elevated BMI (Lagunova et al., 2011). A 
Meta-analysis conducted  in Brazil reported a high prevalence of vitamin D deficiency 
with a significant association between low 25(OH)D levels and obesity irrespective of 
age and latitude (Pereira-Santos et al., 2015). Also, Caucasian women aged 18-31 
years old had higher levels of  fasting serum PTH and their 25(OH)D levels were 
associated with increased fat mass (Gunther et al., 2006). PTH is synthesized in 
response to low calcium levels and its concentrations are also increased in vitamin D 
deficiency states. Results of the present study have shown significant and inverse 





correlation between 25(OH)D levels and increased PTH concentration in the female 
group, but this was not observed in the male group. In line with the present results, a 
population study has reported an association between obesity, low serum 25(OH)D 
levels, increased PTH and low active vitamin D (1.25-(OH)2D3) levels (Parikh et al., 
2004). Increased PTH may be attributed by high frequency of vitamin D deficiency and 
degree of obesity in females compared to males respectively. 
The causal effect of the relationship between vitamin D deficiency and obesity is poorly 
understood, although accumulating evidence suggests that vitamin D may be 
sequestrated into the increased adipose tissue compartments in the obese individuals 
thus limiting its bioavailability in the circulation (Bolland et al., 2007). Low vitamin D 
status has been associated with glucose intolerance and occurrence of T2DM in 
several populations. Several studies have reported  that patients with T2DM or glucose 
intolerance exhibit lower 25(OH)D levels as compared to healthy controls (Hurskainen 
et al., 2012); (Kostoglou-athanassiou et al., 2013); (Lakshmi et al., 2015); (Rahman et 
al., 2017). In contrast, 25(OH)D levels were significantly very low in both males and 
females in the hyper-glycaemic and normo-glycaemic groups in the present study. 
The 25(OH)D levels in the present study were insufficient and serum VDBP levels did 
not differ among the glycaemic groups. These results suggest that this population may 
require vitamin D supplementation to maintain adequate 25(OH)D levels. Moreover, 
findings of the present are in accordance  with those reported in a Saudi Arabian study 
which also observed  low 25(OH)D levels in both T2DM patients  and in healthy 
controls (Alhumaidi et al., 2013). The possible role of vitamin D deficiency in the 
pathogenesis of T2DM is not completely understood and evidence is sparse and 
inconclusive. The proposed mechanisms in which vitamin D deficiency predisposes to 
T2DM may be either through direct action on vitamin D receptor activation or indirectly 
via calcium hormones and inflammation (Thorand et al., 2011); (Sung et al., 2012).  
Both T2DM and obesity are conditions that are associated with inflammation , with  
systemic inflammation being found to increase insulin resistance  (Hribal et al., 2014). 
C-reactive protein (CRP) is an acute phase protein synthesized in response to 
inflammation or infection. A rise in CRP levels in the range of 3-10 mg/l indicates the 
presence of chronic low-grade inflammation and  is frequently observed among obese 
subjects and  is involved in the development of insulin resistance (Hribal et al., 2014).  
Vitamin D has anti-inflammatory effects and low levels have been shown to be 
associated with a rise in CRP and increased proinflammatory cytokines such as IL-6 





and TNFα, which impairs insulin signaling thus leading to systemic inflammation. The 
present study has demonstrated a strong inverse correlation between CRP and low 
25(OH)D levels in females compared to males (P=0.0037), and also a strong inverse 
correlation with HOMA-IR in females only. Multiple linear regression revealed that 
CRP is a predictor of low 25(OH)D. This is evident because all females in the present 
study were obese, but males were overweight. Hence the increased CRP and its 
correlation with low 25(OH)D levels in females may be indicative of systemic 
inflammation leading to insulin resistance. Epidemiological studies have showed 
significant and inverse correlation between low 25(OH)D levels with raised fasting 
blood glucose and severity of insulin resistance (Zittermann, 2006); (Pittas et al., 
2010).  
In the present study, low 25(OH)D levels were significantly and inversely correlated 
with high 2 hr BG, HbA1c, FBI, 2 hr BI and HOMA-IR in Normo-glycaemic females (All, 
P≤0.049).  Low 25(OH)D levels were further significantly and inversely correlated with 
FBG and HbA1c (All, P≤0.011) and positively correlated with post 2 hr BI, (P=0.022) 
in screen-detected DM female subjects. In Nomo-glycaemic males low 25(OH)D levels 
were significantly and inversely correlated with post 2 hr BG (P=0.012) and inversely 
with FBI in screen-detected DM group (P=0.010). These results are  consistent with 
those reported in a Bangladeshi population in which they found a significant negative 
correlation between 25(OH)D levels and fasting blood glucose among T2DM patients 
(Rahman et al., 2017). Additionally, low 25(OH)D levels were negatively correlated 
with fasting plasma glucose and HOMA-IR in Egyptian patients (Clemente-Postigo et 
al., 2015). 
However, in the present study, multiple linear regression analysis revealed that FBG 
and FBI were not associated with low 25(OH)D levels in both normo-glycaemic and 
hyper-glycaemic males and females. These findings are  inconsistent with data from 
the NHANES (III) study which reported an inverse association between serum 
25(OH)D with fasting blood glucose, post 2 hr BG, fasting blood insulin and prevalence 
of T2DM (Scragg et al., 2004). Another study also showed that low 25(OH)D levels 
were associated with post 2 hr blood glucose (Hurskainen et al., 2012). 
No correlation was observed between serum VDBP levels and glycaemic indicators in 
the present study. A significant positive correlation with FBI and post 2 hr BI was 
observed in screen-detected DM females, whereas in normo-glycaemic female 





subjects there was a positive correlation between serum VDBP levels with post 2 hr 
BG and 2 hr BI (All, P≤0.084). Also, near-significant positive correlation with HbA1c 
was observed in normo-glycaemic males (P=0.097) and significant inverse correlation 
with post 2 hr BG was observed in pre-DM males (P=0.011). 
In contrast to our results a more recent study in a Thai population have shown low 
serum VDBP levels in metabolic syndrome patients compared to healthy controls, and 
has demonstrated significant negative correlation of serum VDBP levels with systolic 
blood pressure, fasting blood glucose and age (Karuwanarint et al., 2018). Moreover, 
evidence from several studies suggest that vitamin D deficiency is associated with 
CVDs (Holick & Chen, 2008b) (Engelman et al., 2010) through its effect on lipid profiles 
(Saedisomeolia et al., 2014).  There is high prevalence of dyslipidaemia in patients 
with T2DM, which put them at a high risk for development of cardiovascular diseases 
(Vinodmahato et al., 2011). 
Interestingly, the lipid profile parameters including triglycerides, LDL-C, and 
Cholesterol were significantly increased in both genders (All, males P≤0.0300, females 
P<0.0001) in the hyper-glycaemic sub-groups (All, p<0.0001), whereas HDL-C was 
significantly decreased in both males and females in the hyper-glycaemic sub-groups 
(All, p≤0.0308). Similarly, (Saedisomeolia et al., 2014) has reported elevated TG, LDL-
C, TC and reduced HDL-C levels in 108 Iranian patients with T2DM. In the present 
study, low serum 25(OH)D levels were significantly inversely correlated with increased 
TG, LDL-C, TC and reduced HDL-C in females, but in males there was a near 
significant inverse correlation with TG, LDL-C and TC only. Evidence suggest that 
hyperlipidaemia in females may be attributed to the effects of sex hormones on body 
fat distribution thus leading to differential altered lipoproteins compared to males 
(Sibley et al., 2006).  
In the present study, low 25(OH)D levels were significantly and inversely correlated 
with TG, LDL-C and positively correlated with HDL-C in normo-glycaemic, prediabetic 
and known-diabetic females (All, P≤0.0490). However, in pre-diabetic male patients 
25(OH)D levels were significantly and inversely correlated with HDL-C, but near 
significant correlation was observed in screen-detected DM males. Similarly, a study 
in Americans have shown that low 25(OH)D levels are inversely correlated with TC, 
TG, LDL-C and positively correlated with HDL-C (Gaddipati et al., 2011). In the present 
study multiple linear regression found a negative association between low 25(OH)D 
levels and increased LDL-C levels in both normo-glycaemic and hyper-glycaemic 





groups. Unlike the findings of the present study, low 25(OH)D levels were positively 
associated with increased TC, HDL-C and LDL-C and negatively associated with TG 
among 1808 Norwegian subjects (Jorde et al., 2010).  Vitamin D deficiency was 
significantly associated with increased diastolic blood pressure, TG, and reduced 
HDL-C in Caribbean population (Vélayoudom-céphise et al., 2011), whereas in 
Iranians only increased TG was associated with low 25(OH)D levels (Saedisomeolia 
et al., 2014).  
In the present study serum VDBP (µg/mL) showed significant positive correlations with 
triglycerides (mmol/L) in normo-glycaemic and in pre-DM female subjects (All, 
P≤0.013). Furthermore, no correlation was observed with  lipids in any of the females  
glycaemic sub-groups, but significant positive correlations with LDL-C (mmol/L) and 
Cholesterol (mmol/L) was observed in normo-glycaemic males (All, P≤0.002) and a 
significant positive correlation with HDL-C (P=0.018) and a near-significant positive 
correlation with Cholesterol (mmol/L) (P=0.103) in screen-detected DM males. 
Multiple linear regression analysis revealed an association between low 25(OH)D and 
serum VDBP levels in hyperglycaemic females only. There is a lack of data in the 
literature on the association of serum VDBP and diabetes with data being focused 
more on the association between VDBP polymorphisms and increased risk for T2DM.  
 
As stated earlier, evidence from the literature has shown that various risk factors are 
implicated in the onset and progression of T2DM. Moreover, several genes involved 
in its metabolic pathway have been regarded as good candidates for its onset 
(Barroso, 2005), among these, VDR gene is considered as an important candidate 
gene for susceptibility to T2DM. This is due to expression of VDR on various cells 
involved in the regulation of glucose metabolism (Palomer et al., 2008), and the fact 
that vitamin D modulates expression of insulin receptor genes, insulin secretion and 
exerts its action on target cells through binding to VDR (Al-Daghri, Al-Attas, Alokail, 
Alkharfy, Draz, et al., 2012). Hence variation in VDR may possibly contribute to 
susceptibility to T2DM. The present study has investigated the association between 
VDR polymorphisms Fok1 (rs2228570), Taq1 (rs731236) and Apa1 (rs7975232) in 
diabetic (T2DM) and non-diabetic patients in the mixed ancestry population group.  
The results of the present study have shown non-significant differences in the allelic 
and genotypic frequencies of the VDR gene (Fok1 (A>G), Apa1 (C>A), and Taq1 





(A>G)) SNPs between T2DM and non-diabetic patients (Table 5.10A and B). 
Interestingly, these alleles and genotypes frequencies were similar to those reported 
in this population previously (Babb, van der Merwe, Beyers, Pheiffer, Walzl, Duncan, 
van Helden & Hoal, 2007). Fok1 variant allele G encodes 424 amino acid base long 
protein compared to variant allele A which encodes 427 amino acid long protein 
(Uitterlinden et al., 2004); (Palomer et al., 2008). Studies have suggested that shorter 
proteins have higher transcriptional activity which in turn increases binding affinity for 
active vitamin D (1.25-(OH)2D) (Palomer et al., 2008). Hence this can reduce the risk 
for T2DM by improving insulin sensitivity, insulin secretion and insulin resistance. 
Results of the present study have further shown that variant allele G of the Fok1 SNPs 
was not associated with T2DM (75.4%), compared to non-diabetics (73.9%), and the 
variant genotype GG frequency of the Fok1 SNPs in T2DM (58.5%) was not 
significantly different from Non-diabetics (55.1%).  
In contrast to our results , a more recent study has shown an association of the variant 
G allele and variant AG and GG genotypes of the Fok1 SNPs and variant allele T and 
TT genotypes of the Bsm1 SNP with increased risk for T2DM in an Emirati population 
(Al et al., 2018). These results were corroborated in a meta-analysis of cross-sectional 
studies in Caucasians and East Asians which showed an association between Fok1 
SNPs with increased risk for T2DM more especially in East Asians (Wang et al., 2012). 
Also, Fok1 SNPs were associated with an increased risk for T2DM in Kashmir Valley 
population (Malik et al., 2017) from India. However, other studies failed to reproduce 
the association between VDR SNPs and T2DM. For example, (Banerjee et al., 2009) 
using Fok1, Apa1 and Bsm1 demonstrated that there is no association between 
polymorphisms in the VDR gene with T2DM risk in North Indians. Moreover, (Cyganek 
et al., 2006) also failed to demonstrate such an association in a Polish population. 
Previous studies have shown that polymorphisms within intron 8 and exon 9 of the 
VDR affect the expression of this protein (Ogunkolade et al., 2002). For example, A 
allele of the Taq1 SNP was associated with an increased VDR protein expression in 
Saudi Arabians (Al-Daghri et al., 2012). In the present study, Apa1 variant allele A was 
not associated with T2DM (61.3%) compared to non-diabetics (61.5%), and there was 
non-significant difference in the variant genotype AA frequency between T2DM 
(40.1%) and non-diabetics (38.0%). In contrast, Apa1 genotypes were  associated with 
T2DM in an American population (Oh et al., 2002). Moreover, In the present study, 





Taq1 variant allele G was not associated with T2DM (28.5%) compared to Non-
diabetics (28.2%), there were non-significant difference in the variant genotype GG 
frequency between T2DM (6.9%) and Non-diabetics (8.5%).  
On the contrary, the variant AG genotype of the Taq1 SNP and variant genotype CC 
and CT of the Bsm1 SNP were associated with increased risk for T2DM in Saudi 
Arabian patients compared to healthy controls (Al-Daghri et al., 2012). Similarly, 
variant A allele and AG allele of the Taq1 polymorphism were associated with 
increased risk for T2DM in obese patients in Iraq (Al-darraji et al., 2017). Even though 
results of the present study are in accordance with those shown in North Indians 
(Banerjee et al., 2009), Polish (Cyganek et al., 2006) and French (Dilmec et al., 2010) 
which demonstrated no association, but they have presented some differences from 
the results of the present study. For example, in Caucasians the variant genotype AA 
of the Apa1 polymorphism was marginally high in T2DM patients compared to controls 
(Oh et al., 2002). 
Hence, it could be summarised that Bsm1 and Taq1 polymorphisms are important in 
the pathogenesis of T2DM through their effects on VDR gene expression level. The 
discrepancies of the results reported in the literature and those of the present study 
could possibly be explained by genetic differences and environmental exposure. Since 
majority of studies were performed in homogenous populations groups, the present 
study in contrast  was performed in a population that comprised of many ancestry 
descendants including Khoisan (32-43%), Bantu speaking African (20-36%), 
European (21-28%) and Asian (9-11%) (de Wit et al., 2010).  
VDR gene variants are associated with metabolic complications involved in the 
development of T2DM such as dyslipidaemia, obesity and other cardiovascular risk 
factors. For example, variant AA genotypes of the Apa1 polymorphisms were 
associated with glucose intolerance in T2D patients (Oh et al., 2002). Taq1 and Bsm1 
genotypes were frequent in T2DM patients compared to controls and were associated 
with increased total Cholesterol and lower HDL-C in Saudi Arabians (Al-Daghri et al., 
2012). In addition, variant genotype FF of the Fok1 SNPs was significantly associated 
with increased TC, TG, LDL-C and HDL-C in Moroccans patients with T2DM (Abdeltif 
et al., 2014). VDR polymorphisms were not associated with either vitamin D 
deficiency/insufficiency in the present study. 





However, vitamin D prevalence of vitamin D deficiency was associated with the variant 
f (T) allele of the Fok1 SNP and aa (AA) genotype of the Apa1 SNP in Caribbean 
patients (Vélayoudom et al., 2011). These results suggest that the f allele of the Fok1 
SNP and AA genotype of the Apa1 may be protective against vitamin D deficiency. 
The present study demonstrated no significance difference in the genotype or allele 
frequency distribution of Fok1 (rs2228570), Apa1 (rs7975232) or Taq1 (rs731236) 
SNPs between subjects with optimal Vitamin D (25(OH)D ng/mL) levels and those with 
insufficient/deficient levels (P≥0.2036 and P≥0.6347 respectively). These trends were 
also observed when serum VDBP levels were evaluated against Fok1, Apa1 and Taq1 
genotypes. Also, there was no significance difference in the SNPs frequencies in 
obese and overweight participants. SNP frequencies were insignificantly different 
among patients with moderate/severe insulin resistance compared to normal insulin 
resistance participants in the present study. These results suggest that VDR seems 
not to be a suitable candidate for susceptibility to T2DM mellitus in the mixed ancestry 
population group.  
The present study had limitations. The study design was cross-sectional in nature 
hence association found does not demonstrate a causal relationship. A detailed food 
frequency questionnaire for evaluation of food intake containing vitamin D was not 
administered. Seasonal variation of serum vitamin D levels was not taken into 
consideration. The study had a high female participation compared to males. The 
present study was strengthened by a relatively large sample size. It has comprised of 
varying glycaemic groups. For example, the hyper-glycaemic sub-groups comprised 
of pre-diabetics, screen-detected DM and known DM. The present study was also 
strengthened by the fact that we analyzed both vitamin D levels, its transporter in the 
circulation (vitamin D binding proteins) and the polymorphisms of its receptors on 
target tissue/cells.  





Chapter 7 Conclusion 
The findings of the present study have significant clinical and public health 
implications. The population studied is known to have a high prevalence of obesity, 
hypertension and T2DM. Compelling evidence from epidemiological and observational 
studies have shown that vitamin D deficiency is common in obese individuals and is 
associated with increased risk for insulin resistance and T2DM. In the present studied 
population vitamin D deficiency and insufficiency were highly prevalent. In addition, 
Obesity was highly prevalent in females compared to males. Overall vitamin D levels 
were insufficient, vitamin D levels were low in both normo-glycaemic and hyper-
glycaemic males and females while serum VDBP was within the normal range. 
Serum VDBP was associated with low 25(OH)D in hyper-glycaemic females only. 
Alleles and genotype frequencies of the VDR gene SNPs (Fok1, Apa1 and Taq1) were 
not significantly different among the normo-glycaemic and hyper-glycaemic groups. 
Therefore, this finding shows that VDR gene SNPs are not associated with T2DM in 
the studied population. Low 25(OH)D was associated with increased LDL-C and PTH 
in both male and females irrespective of T2DM. low 25(OH)D was not associated with 
any of the T2DM phenotypes and metabolic traits. Overall conclusion, Low 25(OH)D 
levels were not associated with serum vitamin D binding protein and VDR 
polymorphisms in T2DM patients in the mixed ancestral population group.  
Vitamin D supplementation may carefully be recommended to increase the 25(OH)D 
levels and to observe its effect on the regulation of glycaemic status in the studied 
population. In addition, further genetic studies should be designed to identify genes 
associated with increased susceptibility for T2DM and obesity in this population. Other 
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We would like to invite you to participate in a research study that involves genetic analysis and 
possible long-term storage of blood or tissue specimens. Please take some time to read the 
information presented here which will explain the details of this project. Please ask the study staff or 
doctor any questions about any part of this project that you do not fully understand. It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you could be involved. Also, your participation is entirely voluntary and you are free to decline to 
participate. If you say no, this will not affect you negatively in any way whatsoever. You are also free 
to withdraw from the study at any point, even if you do agree to take part initially. 
This research study has been approved by the ethics Faculty of Health & Wellness Sciences of the Cape 
Peninsula University of Technology and it will be conducted according to  international and locally 
accepted ethical guidelines for research, namely the Declaration of Helsinki, and the SA Department 
of Health’s 2004 Guidelines: Ethics in Health Research: Principles, Structures and Processes. 
Genetic material, also called DNA or RNA, is usually obtained from a small blood sample. Occasionally 
genetic material is obtained from other sources such as saliva or biopsy specimens. (A biopsy is a tiny 
piece of tissue that is cut out e.g. from the skin or from a lump, to help your doctor make a diagnosis.) 
Genes are found in every cell in the human body. Our genes determine what we look  like  and 
sometimes what kind of diseases we may be susceptible to. Worldwide, researchers in the field of 
genetics are continuously discovering new information that may be of great benefit to future 
generations and also that may benefit people today, who suffer from particular diseases or conditions. 





This research study seeks to address the increasing problem of diabetes and cardiovascular diseases 
such as heart attack and stroke amongst the mixed ancestry or coloured population of South Africa. 
In this study we shall identify people with diabetes and those at high risk of diabetes as well as 
investigate the environmental and genetic risk factors that predispose some individuals to the 
development of diabetes and cardiovascular diseases. Examples of environmental factors include 
body weight, diet, and physical activity. Additionally, this project aims to investigate whether oral 
health is a risk factor for diabetes and cardiovascular diseases. In this study we shall investigate 
whether some individuals have early cardiovascular diseases by using an ultrasound machine. This 
project also aims to collect genetic material (blood) to analyze for certain variants and to store excess 
material for future research. When a large group of patients with similar diseases has been collected, 
meaningful research into the disease processes may become possible. 
Our research team has previously conducted a similar research study involving the coloured 
community and found out that more that 18 out of 100 individuals had diabetes but did not know. We 
also found that some of the risk factors associated with diabetes in other populations were not 
necessary the same as those affecting the coloured population of South Africa. You have therefore 
been invited to take part in this research study to assist in establishing the risk factors for diabetes 
and cardiovascular diseases affecting the coloured people of South Africa. 
A. You will be requested to provide information about your medical history, family history and 
information on eating, drinking and smoking habits. Completion of the questionnaire will take no 
longer than 30 minutes. 
B. You shall be requested to provide a record of the medication you are currently taking, 
therefore if you are taking chronic medication, you shall be requested to provide this to the research 
team to record the medication. 
C. Measurement such as weight, height, waist and hip will be done. 
D. Fasting Venous Blood (20ml) will be collected thereafter you will be asked to drink a glucose 
solution (glucose content 75g). After two hours another venous blood (10ml) will be collected. The 
blood will be used to determine whether you have diabetes or you are at high risk for developing 
diabetes. 
E. The other tests that will be determined from your blood sample are:  Cholesterol, triglycerides, 
creatine levels to assess your kidney function, liver enzymes to assess your liver, and biochemical 
markers for inflammation. 
F. A finger prick blood sample (a drop of blood), to be taken at the same time of the first venous 
blood sample, may also be required from you. The finger prick blood sample will be used to test for 
diabetes or the risk of developing diabetes on a point-of-care test instrument. Researchers will 
compare the finger prick point-of-care diabetes test with that of the send away venous blood 
laboratory test and would be able to establish whether the point-of-care test provides the same 
accurate results as that of the laboratory. Point-of-care testing may in the future be used to provide 
fast and accurate results without the need to send blood away to a laboratory for processing. This may 
be of benefit to people undergoing testing for diabetes as results would be available within a few 
minutes. 
G. The remainder of the blood sample will be used for genetic and future research studies. The 
serum and DNA may be stored for several years until the technology for meaningful analysis becomes 
available. No pharmaceutical agent (medication) will be tested in the study. 





H. For oral health,  research  study  personnel  will  extract  wooden  toothpick,  flocked  brush,  
and mouthwash saliva samples from you to test for the presence of Porphyromonas gingivalis as an 
indicator for periodontal disease. Flocked brush and wood toothpick sampling will involve inserting 
devices in the subgingival crevice between the last upper premolar and the first upper molar. The 
device will sweep down the anterior surface of the first upper molar with the direction of motion away 
from the gum to minimize any potential discomfort. Mouthwash sampling will involve rinsing with 10 
ml sterile saline solution for 20 seconds. 
I. Early cardiovascular diseases will be performed by means of an ultrasound machine. 
J. The research team will follow up on you on a yearly basis and some of these test may be 
repeated. The investigators wish to follow you up for your entire life. In the unfortunate event that 
you are deceased during the study period. The study team will review stats SA data and/or medical 
records to ascertain whether the cause of death was due to diabetes or cardiovascular diseases. . If 
you do not wish to be followed up on a yearly basis and your Statistics SA and/or medical records not 
to be accessed in the unfortunate event that you are deceased whilst being a participant in the study, 
you will have an opportunity to request that it be not accessed when you sign the consent form. 
K. Radio imaging techniques will be done on consenting subjects. These include (i) ultra sound 
to assess whether you have signs of early cardiovascular diseases, (ii) computed tomography scan (CT-
scan) to accurately assess the fat content that is dangerous for cardiovascular diseases (iii) Dual-energy 
X-ray absorptiometry (DXA) devices will be used to study the morphology of the liver. These radio 
imaging techniques involve radiation which can be harmful if one is exposed excessively. For this study 
a low dose radiation will be used for acquisition of the images thereby minimizing radiation exposure 
to the participant. . If you do not wish to undergo any of these radio imaging techniques, you will have 
an opportunity to decline when you sign the consent form. 
L. An eye examination will be done to test your eye vision and any other abnormalities inthe 
eye. For this examination, drops placed in your eyes widen (dilate) your pupils to allow the doctor to 
better view inside your eyes. The drops may cause your close vision to blur for a short while. 
A slight bruising might occur after blood has been drawn from the arm but this will heal quickly. After 
the administration of the glucose solution, you may feel nauseous and dizzy in which case you must 
notify the medical personnel. A medical nurse or doctor will be present on all occasions. You may also 
learn that you have diabetes, in which case you will be referred to your health care giver with the 
results for further treatment and management. If during the study it is discovered that you have 
changes in your genes that may lead to a serious disease, a genetic counsellor at the expense of the 
principal investigators will counsel you. Radio imaging techniques such as the CT-scan involves 
radiation which can be harmful if one is exposed excessively. For this study  a low dose radiation will 
be used for acquisition of the images thereby minimizing radiation exposure to the participant. 
Your personal results will be made known to you only if they indicate that you may: 
• Have diabetes, thereafter, you will be referred to your local health centre or general 
practitioner for further investigations and treatment. 
• Have a condition or predisposition to developing diabetes that is treatable or avoidable 
e.g. by a lifestyle modification. 
• Need genetic counselling. 





 However, participants with normal results who wish to know their results are free to contact 
the research team and their results will be given upon written request. 
The blood samples may be stored indefinitely to accommodate new technologies that may develop. 
In the event that a technology is not available in South Africa to analyse your blood sample, your blood 
specimen may be sent to another country with the technology either now or at a later date. However, 
if your specimen is to be sent to another country, permission to do so will be sought from relevant 
bodies. Your blood specimen will be stored at the Cape Peninsula University of Technology. 
Your   blood    will    only    be    used    for    genetic    research    that    is    directly    related    to 
Diabetes and cardiovascular diseases. Also if the researchers wish to use your stored blood for 
additional research in this field they will be required to apply for permission to do so from the ethics 
Faculty of Health & Wellness Sciences of the Cape Peninsula University of Technology. If you do not 
wish your blood specimen to be stored after this research study is completed you will have an 
opportunity to request that it be discarded when you sign the consent form. 
Your identity will be recorded once and kept confidential throughout. This is to allow the principal 
investigators to convey information that may be beneficial to you. Access will be limited to the 
principal investigators by assigning a special study code to all your data and blood samples. This means 
that your sample will be identified with a special study code that will remain linked to your name and 
contact details. However, during the entire research study, your blood specimens will be anonymised 
and the research staff won’t be able to associate it with your name and contact details. You shall also  
be supplied this code so that if at anytime the investigators need to contact you, you may only identify 
yourself using your special code. Any scientific publications, lectures or reports resulting from the 
study will not identify you. 
Some insurance companies may mistakenly assume that taking part in research indicates a higher risk 
for disease. Thus no information about you or your family will be shared with such companies. 
You will not be paid to take part in this study although your out-of-pocket expenses may be 
reimbursed. The expenses that will be covered by the research team are those that include 
transportation to a hospital radiography department should you consent to radio imaging. 
You should inform your family practitioner or usual doctor that you are taking part in a research study. 
You can contact 
 Prof T Matsha at 021 959 6366 or matshat@cput.ac.za, 
If you have any further queries or encounter any problems, you can also contact the Cape Peninsula 
University of Technology Health and Wellness Sciences Research Ethics Committee, 
Chairperson: Prof Engel-hills at 0219596570 or EngelhillsP@cput.ac.za or 
You will receive a copy of this information and consent form for your own records if it is requested. By 
signing below, I …………………………………..…………. agree to take part in a research project that includes 
genetic research study entitled (PROGRESSIVE RESEARCH ON RISK FACTORS OF TYPE 2 DIABETES AND 
CARDIOVASCULAR DISEASES IN SOUTH AFRICA). 
I declare that: 
• I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately answered. 





• I understand that taking part in this study is voluntary and I have not been pressurised to take 
part. 
• I have received a signed duplicate copy of this consent form for my records. 
I agree that my blood or tissue sample can  be stored  indefinitely after the project is completed but 
that it is anonymised with all possible links to my identity removed, and that the researchers may then 
use it for additional research in this or a related field. Once my sample is anonymised, my rights to 
that sample are waivered. My sample may be shipped to another laboratory in SA or abroad to be 
used in other research projects in this or a related field 
OR  
I agree that my blood or tissue sample can be stored indefinitely, but I can choose to request at any 
time that my stored sample be destroyed. My sample will be identified with a special study code that 
will remain linked to my name and contact details. I have the right to receive confirmation that my 
request has been carried out. 
OR 
Please destroy my blood sample as soon as the current research project has been completed. 
 I consent that the research team may follow me up for yearly check-up AND in the unfortunate event 
that I am deceased whilst still part of the study, I consent that the team may access Statistics SA and/or 
my medical records to ascertain whether the cause of my death was due to diabetes or cardiovascular 
diseases. 
OR 
I do not consent to follow me up for yearly check-up BUT in the unfortunate event that I am deceased 
whilst still part of the study, I consent that the team may access Statistics SA and/or my medical 
records to ascertain whether the cause of my death was due to diabetes or cardiovascular diseases. 
OR 
I do not consent to follow me up for yearly check-up AND in the unfortunate event that I am deceased 
whilst still part of the study, I do not consent that the team accessing Statistics SA and/or my medical 
records to ascertain whether the cause of my death was due to diabetes or cardiovascular diseases. 
 □ I consent to ultra sound techniques to assess if I have early cardiovascular diseases 
□ I do not consent to ultra sound techniques that assess if I have early cardiovascular diseases 
AND 
□ I consent  computed  tomography  scan  (CT-scan)  to  accurately  assess  the  fat  content  that  
is dangerous for cardiovascular diseases 
□ I do not consent to computed tomography scan (CT-scan) that accurately assess the fat 
content that is dangerous for cardiovascular diseases 
AND 
□ I consent to Dual-energy X-ray absorptiometry (DXA) used to study body composition. 
□ I do not consent Dual-energy X-ray absorptiometry (DXA) used to study body composition  





Signed at (place) ............................................... on (date) ...................................................... 
 
 
Finger print     .........................................................    .......................................................... 
                         Signature of participant                        Signature of witness 
 I (name) ………………………………………………… declare that: 
• I explained the information in this document to …………………..……………... 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research as discussed 
above. 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign the 
declaration below. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
............................................................................ .......................................................................... 
Signature of investigator                               Signature of witness 
I (name) ………………………………………………… declare that: 
• I assisted the investigator (name) …………………………. to explain the information in this 
document to (name of participant) …………………………….. Using the language medium of 
Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
............................................................... .......................................................................... 
Signature of interpreter                                      Signature of witness 
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